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Despite the success of immunotherapy in many types of cancer, pancreatic adenocarcinoma 
(PDAC) has yet to benefit. Innate immune cells are critical to antitumor 
immunosurveillance and recent studies have revealed that these populations possess a form 
of memory, termed trained innate immunity, which occurs through transcriptomic, 
epigenetic, and metabolic reprograming. Though trained innate immunity has mostly been 
investigated in the context of infection, the induction of trained innate immunity could also 
protect against tumors, and specifically pancreatic tumors.  Here, we demonstrate that 
yeast-derived particulate β-glucan, a known inducer of trained immunity, traffics to the 
pancreas following IP administration. This causes a CCR2-dependent influx of newly 
characterized monocytes/macrophages to the pancreas which display features of trained 




derived factors, and show enhanced phagocytosis and ROS-mediated cytotoxicity against 
pancreatic tumors. In orthotopic models of pancreatic cancer, mice trained with β-glucan 
show reduced tumor burden and prolonged survival which is further enhanced when 
combined with anti-PD-L1 immunotherapy. Cumulatively, these findings not only add 
novel characterization to the dynamic mechanisms, scope and localization of peripheral 
trained immunity, but also identify a direct application of trained immunity to cancer that 
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The diagnosis of pancreatic ductal adenocarcinoma (PDAC)  is a devastating one, with 
only 10% of patients surviving past 5 years [1]. Although the survival rate since 2014 has 
increased from 6% to 10%, pancreatic cancer remains refractory to the majority of 
currently available therapeutics. In addition, as the demographics of the United States shift, 
it is projected that pancreatic cancer will become the second leading cause of cancer-related 
mortality by 2030 and thus presents a significant future challenge for clinicians [2]. 
Pancreatic cancer is particularly lethal due to the fact that in early stages there are seldom 
clinical symptoms, which results in 75-80% of patients being diagnosed with advanced, 
non-resectable disease [3, 4].  Even in patients who are eligible for resection, the 5 year 
survival rate is only 20-25% [4].  Furthermore, pancreatic cancer has shown little 
responsiveness to immunotherapies which have shown remarkable effects in other solid 
tumors [5-8]. The Phase I and II clinical trials using CTLA-4 and PD-1 inhibitors both 
alone and in combination have been deemed ineffective for the treatment of PDAC, which 
is likely explained by the non-immunogenic nature of PDAC [9-11].  
A major challenge to the successful application of immunotherapy in PDAC is 
overcoming the immunosuppressive pancreatic tumor microenvironment (TME). PDAC is 
characterized by a dense pro-tumorigenic desmoplastic stroma, an abundance of 
immunosuppressive cell subsets within this stroma such as tumor-associated macrophages 
(TAMs), regulatory T-cells (T-regs), and myeloid-derived suppressor cells (MDSCs), a 




microenvironment [12-14].  Together these conditions make it exceptionally 
challenging to effectively deliver immunotherapies to the pancreas and for these 
therapeutics to successfully activate anti-tumor immune responses if they do arrive there.  
Therefore, novel therapeutics are needed that can not only specifically target the pancreas, 
but that can also infiltrate the dense desmoplastic stroma and that are capable of inciting 
robust anti-tumor immune responses despite the immunosuppressive TME.   
-glucans are a group of biologically active polymers of glucose that are found in the 
cell wall of bacteria, fungi, edible mushrooms, yeast, barley, oats, wheat and rye [15, 16]. 
Though -glucan can come in many forms, only molecules with a (1,3)-linked D-glucose 
backbone can act as a biological response modifier (BRM) [17]. Yeast-derived -glucan is 
one such example of a BRM, and is made of a linear backbone of (1,3)-linked D-glucose 
molecules with (1,6) side chains of variable length [18]. This form of -glucan has been 
extensively studied for its ability to reprogram immunosuppressive M2 macrophages into 
activated, anti-tumor M1 macrophages [19]. More recently however, -glucan has also 
been identified as an inducer of a program of innate immune memory, termed trained innate 
immunity [20]. Trained immunity is the concept that when innate immune cells are exposed 
to specific initial stimuli, such as -glucan or the Bacillus Calmette-Guérin (BCG) vaccine, 
they will undergo metabolic, epigenetic and transcriptomic reprogramming [21-23]. Due 
to this reprogramming, when these cells then come into contact with a secondary, 
heterologous stimulus, the cell will exhibit enhanced reactivity by means of increased 
cytokine production [24, 25].  
        In this study, we characterize a novel trafficking mechanism of yeast-derived 




This results in an influx of trained innate immune cells with an activated phenotype into 
the pancreas that notably do not cause pancreatic destruction or signs of pancreatitis. We 
show that these trained innate immune cells have antitumor effects, which results in 
significant tumor control with prolonged survival in orthotopic pancreatic tumor models. 
Given the failure of the majority of immunotherapies alone and in combination to treat 
PDAC and the difficulty of targeting these therapeutics to the pancreas, these findings 
provide a potential breakthrough in not only targeting the pancreas with an immunotherapy, 
but also in recruiting anti-tumor, pro-inflammatory immune cells to the PDAC TME.  
 
Myeloid Cells in the Tumor Microenvironment 
There are two arms of the immune system: the innate and the adaptive. Of the two, the 
innate immune system is the most evolutionarily conserved arm, and generates rapid, non-
specific inflammatory responses due to signaling by Pattern Recognition Receptors (PRRs) 
such as Toll Like Receptors (TLRs). Pathogen Associated Molecular Patterns (PAMPs), 
which are conserved molecular motifs of pathogens such as bacteria, viruses, and fungi can 
bind to PRRs which will induce innate immune cell activation [26]. Prototypical examples 
of PAMPs include bacterial lipopolysaccharides (LPSs) and endotoxins expressed on the 
cell membrane of gram-negative bacteria. Engagement of PRRs by PAMPs initiates 
intracellular signaling cascades which result in the production of diverse pro-inflammatory 
molecules. This response not only targets the invading pathogen, but also is requisite for 
the activation and recruitment of adaptive immune responses [27].  The innate immune 
system includes macrophages, Dendritic Cells (DCs), Natural Killer (NK) cells, mast cells, 




complement cascade. Importantly, while the innate immune system may have 
evolutionarily evolved to detect foreign invaders such as bacteria and fungi, these pathways 
also participate in the detection of tumor cells [28]. 
 Adaptive immune responses often steal the spotlight with regards to anti-tumor 
immunity, and new therapies that promote antitumor immunity have focused primarily on 
enhancing adaptive immune responses. For example immune checkpoint inhibitors such as 
anti-Programmed cell Death 1(PD-1) monoclonal antibodies (mAbs) which focus on 
activating T-cells in the tumor microenvironment (TME) and chimeric antigen receptor 
(CAR) T-cell infusions have been two of the most studied recent innovations in cancer 
research [29-31]. Despite this focus on adaptive immune responses, it is important to 
remember that the activation status of T-cells is not autonomous, but instead closely 
controlled by innate immune cells within the TME. The importance of T-cells in antitumor 
immunity have been demonstrated by a positive correlation between tumor infiltrating T-
cells and prognosis in several cancer types [32-34]. However, in order to generate antigen-
specific T-cells and to initiate T-cell responses, Antigen Presenting Cells (APCs) such as 
DCs and macrophages are required. In this way, though adaptive cells may exert significant 
anti-tumor functions, these effects are dependent on the control and signaling of innate 
immune cells. Though there are many innate immune cell types that play an important role 
in the pathogenesis of tumors, here macrophages and monocytes will be discussed in detail 
as these are the innate immune cells that were investigated in relation to trained immunity 
in this project.  
In the context of tumors, three important macrophage/monocyte derivates are tumor 




macrophages [35].  TAMs and MDSCs differentiate from immature peripheral blood 
monocytes which originate from common myeloid progenitors (CMPs) in the bone 
marrow. In the case of MDSCs, the TME will often secrete growth factors, chemokines 
and cytokines that promote the accumulation of immature myeloid cells that upon arrival 
to the TME fail to properly differentiate and proliferate [36]. Circulating monocytes can 
also migrate to different tissues and are capable of replenishing the populations of resident 
tissue-specific macrophages such as Kupffer cells in the liver and alveolar macrophages in 
the lung [37]. Additionally, there are unique subsets of resident macrophages, such as glial 
cells in the brain, that differentiate from the yolk-sac of a developing embryo and which 
are maintained through local proliferation [38]. Within the tumor microenvironment, 
macrophages of all origins take on a wide array of phenotypes according to factors within 
the TME.  Often however, macrophages in the TME take on pro-tumorigenic roles by 
promoting angiogenesis, immunosuppression, tumor cell invasion and metastasis [39].  
TAMs are often the most abundant population of tumor infiltrating immune cells 
within the TME, and have been associated with a more malignant phenotype and a poor 
prognosis in various tumor subtypes [40-44]. Macrophages are typically thought to exist in 
two polarized states, classically activated (M1) and alternatively activated (M2), though 
realistically the status of macrophages is likely not binary and exists on a sliding spectrum 
between the two activation states. TAMs often exhibit an alternatively activated, M2, 
phenotype where they not only produce anti-inflammatory cytokines such as IL-10, IL-13, 
and TGF-, but also can secrete growth factors such as vascular epithelial growth factor 
(VEGF) and adrenomedullin to directly support angiogenesis [35, 45-47]. These 




of CD8+ and CD4+ effector functions and stimulate the recruitment of regulatory T cells 
(Tregs) which further promotes tumor growth [48]. Through the production of matrix 
metalloproteinases, serine proteases, and cathepsins, TAMs also modify cell-cell junction 
and disrupt the basal membrane which results in increased capability of tumor cells to 
invade the primary tumor site and also migrate to distant places to form metastases [49-
51]. Finally, TAMs are also involved in resistance to chemotherapy and radiotherapy 
treatment, which are two of the most heavily utilized treatment modalities in cancer [52-
55].  
MDSCs are a heterogenous group of immature myeloid cells that are not typically 
found in healthy individuals and which are divided into two groups: polymorphonuclear 
(PMN-MDSCs) and monocytic (M-MDSC). M-MDSCs are mononuclear and express high 
levels of Ly6C, a prototypical marker for monocytes, and have very low expression of 
Ly6G, a prototypical marker of neutrophils. PMN-MDSCs on the other hand have a multi-
lobular nucleus, similar to a neutrophil, and have high expression of Ly6G and low 
expression of Ly6C [56]. In chronic inflammatory states such as cancer, pro-inflammatory 
cytokines such as PGE2, M-CSF, G-CSF, GM-CSF, TNF-𝛼, CXCL12, CCL2 and TGF-𝛽 
are released locally by immune cells, stromal cells and tumor cells, which can  impact 
myelopoiesis in the bone marrow and skew the differentiation of immature myeloid cells 
recruited to the TME and halt their ability to differentiate [57-60]. These immature myeloid 
cells take on potent anti-inflammatory phenotypes once they arrive at the TME and are 
known to significantly impair CD4+ and CD8+ T-cell functions, induce NK cell 
dysfunction, prevent DC maturation and induce Tregs [61-66]. Due to these varied 




associated with a shorter overall survival and shorter progression-free survival after 
treatment [67-69].  
Splenic red-pulp macrophages, lung alveolar macrophages, brain microglia, 
epidermal Langerhans cells, large peritoneal macrophages, F4/80hi pancreatic 
macrophages, and cardiac macrophages are all examples of tissue-resident macrophages 
that are known to develop in the yolk sac of embryos independently of hematopoietic stem 
cells (HSCs) and persist in adult tissues [70-73]. Many of these tissue-resident macrophage 
populations are maintained through local proliferation within the tissue, though BM-
derived circulating monocytes can also migrate to tissues and contribute to the tissue 
resident pool of macrophages [74-76]. Like TAMs recruited from the periphery, resident 
macrophages present within the TME also play a role in tumor pathogenesis, though their 
function has not been as well defined as other macrophage populations. For example, 
tissue-resident interstitial macrophages in the lungs of mice were found to significantly 
contribute to the pool of tumor-associated macrophages along with the CCR2-dependent 
recruited macrophages. Additionally, these resident macrophages were found to associate 
with increased tumor growth [77]. Resident macrophages found within the omentum have 
been found to be involved in the metastatic spread of ovarian cancer, and in models of 
PDAC, tissue resident embryonic derived macrophages were also shown to promote 
fibrosis and tumor progression [78, 79]. Even in the brain, resident microglia can exhibit 
anti-tumor functions, however they can also be polarized into immunosuppressive tumor-
supporting cells by specific tumor-derived soluble factors which cause them to contribute 
to tumor angiogenesis, metastasis, dormancy and relapse [80-83].  It has been observed 




in organs that are targets of metastasis formation. For example, in a model of metastatic 
pancreatic cancer, it was found that liver-resident macrophages, Kupffer cells, uptake 
cancer-derived exosomes released from the primary tumor which causes them to secrete 
TGF-𝛽 which activates hepatic stellate cells to transform into myofibroblasts that produce 
fibronectin and recruit immune cells to the liver [84, 85]. Accordingly, it is important to 
distinguish between infiltrating macrophages/ circulating monocyte-derived macrophages 
and resident macrophages in order to fully understand the role of TAMs and to develop 
therapeutics that can effectively target pro-tumorigenic populations.  
 
The Tumor Microenvironment of Pancreatic Cancer 
 PDAC accounts for more than 90% of all pancreatic cancer cases, and is also 
considered to be one of the most aggressive forms of cancer [86]. The long-term clinical 
outcomes of pancreatic cancer are dismal, with the median survival from time of diagnosis 
being 3-6 months in patients who do not receive treatment, and 23 months in patients who 
receive resectional surgery and adjuvant therapy [87].  One reason that pancreatic cancer 
is so deadly is that it is often diagnosed at a late stage of cancer progression, as patients 
often only begin showing non-specific symptoms of the malignancy once it has grown 
large enough to press on the bile duct, resulting in symptoms of jaundice, weight loss and 
anorexia. Pancreatic cancer has a propensity for vascular invasion, rapid and robust 
lymphatic spread, and perineural invasion, meaning that tumor cells surround nerves which 
allows for an alternative route for metastatic spread and results in considerable pain [88]. 
To date, most oncological interventions have failed to produce benefits in long-term 




10-20% of patients with primary tumors in the head of the pancreas, and less than 3% of 
patients with a primary tumor in the head or tail of the pancreas are candidates for resection 
[89-91]. The primary goal of surgical resection is to achieve a negative resection margin 
(R0), however despite this, most patients will develop a recurrence at some point following 
surgical resection [92]. Most patients diagnosed with PDAC will go on to receive some 
form of adjuvant chemotherapy. FOLFIRINOX, which is a chemotherapy regimen 
consisting of Leucovorin, 5-fluotouracil, irinotecan and oxaliplatin, is currently the 
standard adjuvant therapy used and has led to relatively improved outcomes for patients 
with PDAC, however are not sufficient for patients with advanced disease [93, 94]. 
Another particular challenge of PDAC is the high degree of genetic heterogeneity that 
occurs not only between patients but within a single primary tumor [86]. Whereas in lung 
cancer or melanoma where specific genetic mutations, such as EGFR and BRAF, 
respectively, provide excellent targets for interventional therapies, within a single PDAC 
tumor there exist a plethora of mutations that are not shared between patients [95]. 
Additionally, the use of immunotherapy, such as immune checkpoint mAbs anti-CTLA-4, 
anti-PD-1 and anti-PD-L1 have not shown meaningful clinical efficacy and are currently 
not approved for use in patients with pancreatic cancer[6, 96].  
 An important reason that PDAC shows such resistance to commonly used adjuvant 
therapies such as chemotherapy and immunotherapy is the immunosuppressive TME. One 
hallmark of the PDAC TME that is present in both the primary tumor and sites of distant 
metastases is the formation of a dense desmoplastic stroma around the tumor [97]. 
Pancreatic stellate cells are activated by tumor-secreted factors which causes these 




layer around the tumor creates a physical barrier around tumors that limits immune cell 
invasion, promotes tumor angiogenesis and prevents the delivery of systemically delivered 
therapeutics such as chemotherapy and immunotherapy from arriving at the tumor site [98, 
99]. Importantly, PDAC has also been classified as an immunologically “cold” tumor 
meaning that there are few activated anti-tumor T-cells and many immunosuppressive 
Tregs, TAMs and MDSCs. In PDAC, an increased number of Tregs, MDSCs and TAMs 
have all has been associated with promoting PDAC and decreased overall survival [98, 
100-102].  
The dense desmoplastic stroma that decreases the formation of normal vasculature 
also creates a hypoxic environment that effectively recruits immunosuppressive MDSCs 
and assists in their differentiation upon arrival to the tumor site [103]. Patients with PDAC 
exhibit elevated levels of systemic and intra-tumoral MDSCs upon progression of disease, 
and within the TME MDSCs are known to directly suppress the formation of antigen-
specific T-cells and induce Tregs  [104-106]. Upon migration to the tumor site, MDSCs 
have also been shown to differentiate into TAMs, though in murine models of pancreatic 
cancer, 50% of TAMs were also shown to derive from resident macrophage populations 
[78, 107]. Accordingly, analysis of patient’s PDAC samples show that TAMs exhibit M2 
markers such as CD206 and CD163 and secrete high levels of IL-10.  An increased number 
of M2 macrophages is associated with larger tumor size, early recurrence in the liver, local 
recurrence and shorted survival in patients [108]. TAMs have been specifically shown to 
mediate gemcitabine resistance in PDAC by upregulating cytidine deaminase (CDA) 
which is the enzyme responsible for metabolizing gemcitabine after its transport into the 




clinical responses to irradiation and angiogenic inhibitors that are commonly used in 
pancreatic cancer [110].  
Due to the pronounced presence of MDSCs and TAMs within the PDAC TME 
combined with their ability to modulate the function of many other immune cell types, 
myeloid cells within the TME have become the popular target for new anti-cancer 
therapeutics.  Accordingly, it has been shown that depleting tumor-infiltrating 
macrophages can improve chemotherapeutic responses and can relieve 
immunosuppression [111]. Further, while it has been shown that checkpoint inhibitor 
therapies such as anti-CTLA-4 or anti-PD-L1 as a monotherapy are not effective in 
pancreatic cancer, the depletion of TAMs using CSF-1 inhibition synergized with 
checkpoint immunotherapy in PDAC [112]. This provides a convincing rationale to 
develop therapeutics with the goal of reprograming immunosuppressive TAMs and 
MDSCs within the TME in order to unleash the potential of immunotherapy in the setting 
of PDAC.  
 
            Trained Innate Immunity 
Given the critical role that innate immune cells play in the TME of PDAC, we now turn 
our attention to a program of innate immune cell memory, called trained immunity,  
which we propose has the potential to reprogram immunosuppressive myeloid cells 
within the TME. 
 
Throughout evolution, the vast majority of cellular life has existed without the 




contemporary evolutionary adaptation, where until the emergence of jawed fish 500 
million years ago, multicellular organisms existed only with features of innate immunity 
[113, 114]. In the absence of protective memory features of adaptive immunity, plants, 
protists, invertebrates and lower animals evolved ways to protect themselves from 
recurrent infections through the development of systemic acquired resistance (SAR). SAR 
is a program of non-specific protection that is responsible for the observation that following 
inoculation with attenuated organisms, plants are protected from subsequent infections 
from several infectious agents such as fungi, viruses and bacterial pathogens [20, 115]. 
Though ancient, the ability to mount memory-like innate immune responses certainly 
conferred an evolutionary advantage, and this capability was thus retained as evolution 
progressed towards higher vertebrates. These mechanisms underpin the recent discovery 
of trained innate immunity, which posits that mammalian innate immune cells exhibit 
immunological memory of previous pathogen interactions which allows them to better 
respond to and defend against future infections, even from different sources.  
The concept of trained immunity in humans has been present for almost a century. 
In 1931, a Swedish study showed that infants given the Bacille Calmette-Guérin (BCG) 
vaccine against Mycobacterium tuberculosis (TB) exhibited increased survival rates as 
compared to infants that did not receive the BCG vaccine, which could not be only due to 
having immunity to TB [116].  Accordingly, epidemiologists were the first to truly 
characterize trained immunity, where it was noted that recipients of the smallpox vaccine 
were not only protected against smallpox but also other infections such as measles, scarlet 
fever and syphilis [117].  In the late 1900s, a number of additional studies came out which 




and other vaccines, such as the measles vaccine, afforded non-specific protection from later 
heterologous infections [118-122].  
A 2012 study by Quintin et al, more formally confirmed the phenomenon of innate 
immune memory by showing that mice exposed to a low dose of C. albicans induced 
protection against reinfection with C. albicans in Rag-1 deficient mice which lack B and 
T-cells. Further, they showed that the protection to C. albicans was driven by macrophages 
and monocytes, which produced increased levels of TNF-, IL-6, and IL-1 and showed 
an increased phagocytic capacity [123]. Importantly, they also showed that a specific 
component within the cell wall of C. albicans, -1,3-(D)-glucan (-glucan), was 
responsible for initiating these effects. Since then, a great deal of investigation has been 
performed to understand the mechanisms of trained immunity involving -glucan. Human 
and animal studies alike have shown that exposure to -glucan protects from secondary 
infections such as Staphylococcus aureus, TB, Leishmania braziliensis and influenza  
[124-126]. Together, these studies support that -glucan is a potent inducer of trained 
immunity such that when innate immune cells that have been exposed to -glucan are 
exposed to heterologous secondary stimuli of many different etiologies, they will mount a 




[127]. In experiments involving trained immunity, LPS is often used as a secondary 
stimulus, and it is capable of clearly re-stimulating trained cells (Figure I.1).  
Figure I.1: Schematic of trained immunity  
Cells are exposed to an initial training stimulus such as -glucan after which they undergo 
epigenetic, metabolic and mitochondrial reprogramming. When cells are then exposed to 
a secondary stimulus, such as LPS, cells then exhibited responses that are more robust 
than the initial stimulus or the secondary stimulus alone. In effect, the initial stimulus 
causes cells to have a more vigorous response to a secondary stimulus.  
 
Trained innate immunity primarily involves the training of macrophages and 
monocytes, though DCs, Natural Killer (NK) cells and neutrophils have been shown to be 
involved in trained immunity [128-130]. Following induction, it has been observed that 
trained immunity can last from weeks to months. Given that monocytes in the periphery 
are typically short lived, this brought into question whether cells in the periphery are 
directly trained or whether training agents may impact the BM thus leading to more lasting 
effects. Additionally, because cells in the periphery are often terminally differentiated and 




immunity may directly impact the HSCs in the BM which then gives rise to trained cells 
systemically. Fittingly, mice injected with intraperitoneal (IP) -glucan show a biased 
expansion of Lin-Sca1+cKit+ (LSKs) and Multipotent Myeloid Progenitors (MMPs) in the 
BM [131].  Under the current paradigm of trained immunity, the education of HSCs and 
the induction of myelopoiesis in the BM is responsible for the generation of “central” 
memory which then creates a repertoire of innate cells possessing innate immune memory 
features, which then migrate to the peripheral tissues to generate peripheral memory [132, 
133].  
In myeloid cells, loci encoding inflammatory signaling are often in a repressed 
configuration, which is due to low levels of acetylation of histones and minimal RNA 
polymerase II present on enhancer and promoter regions [134, 135]. Following exposure 
to inducers of trained immunity, drastic changes to the accessibility of DNA take place 
through the acetylation of histones and the recruitment of RNA polymerase II,  and result 
in the activation and upregulation of gene expression that can be on the order of 100 times 
higher than baselines levels. These changes are also driven by stimulation-responsive  
transcription factors such as  NF-κB and STAT proteins being recruited to gene promoters, 
which then recruit co-activators such as histone acetyltransferases and chromatin 
remodelers. Together, these significantly increase the accessibility of chromatin, which 
allows for better accessibility of proteins involved in transcription, and ultimately more 
robust responses upon restimulation [127, 136-138].  While inducers of trained immunity 
generally work by increasing the activation status of innate immune cells through these 
described epigenetic modifications, the exact mechanisms can be different among initial 




Dectin-1 is the main receptor for -glucan, and accordingly it was shown that in-
vitro models of trained immunity using -glucan are mediated by dectin-1 signaling [140]. 
Stimulation of myeloid cells with β-glucan has been shown to directly recruit and activate 
SyK kinase through dectin-1 followed by recruitment of Card9 to form the 
Card9/Bcl10/Malt-1 complex that activates the IκB kinase complex resulting in the 
activation of key transcription factor NF-κB. Activation of NF-κB is then able to initiate a 
pro-inflammatory signaling cascade [141-143]. While the specific molecular mechanisms 
of trained immunity are still being investigated, mounting evidence shows that following 
dectin-1 activation, transcriptomic, epigenetic, metabolic, and mitochondrial alterations 
take place which each plays an integral role in the initiation and expression of trained 
immunity.  
Activation of the Dectin-1 receptor by β-glucan has been shown to directly cause 
important changes to the epigenetic status of immune gene promoters. An example of the 
epigenetic priming induced by β-glucan is that upon Dectin-1 activation, nuclear factor of 
activated T-cells (NFAT-1) is dephosphorylated, which results in its translocation through 
the nuclear membrane. NFAT-1 mediates β-glucan-driven epigenetic training by 
upregulating immune gene-priming long non-coding RNAs (IP-incRNAs) which 
culminates in increased levels of trimethylation of histone H3 at lysine 4 (H3K4me3) at 
promoter sites [123, 144]. High levels of H3K4me3 are associated with robust levels of 
gene expression, and so this epigenetic effect results in more vigorous cytokine production 
upon re-stimulation of β-glucan-primed immune cells [145]. Such epigenetic modifications 
driven by β-glucan result in inflammatory genes that are ideally positioned to be rapidly 




This explains why myeloid cells trained with β-glucan release increased levels of TNF-, 
IL-6, and IL-1 following restimulation with LPS.  
Metabolic changes are also a prominent feature of β-glucan induced trained 
immunity, as vital energy metabolites regulate chromatin-modifying epigenetic enzymes, 
methylation, histone modification, and the position of the nucleosome by acting as 
substrates and co-factors. Consequently, the energy state of a cell and the metabolic 
programs that are initiated as a result of β-glucan stimulation tightly modulate the 
transcription of immunogenic genes [146]. The metabolic switch from oxidative 
phosphorylation toward aerobic glycolysis is a key feature of trained immunity, which has 
been shown to be mediated through the AKT/mTOR/HIF1α pathway [21]. Other notable 
metabolic features of trained immunity are a decrease in itaconate, a product of the 
decarboxylation of cis-aconitate, and increased fumarate and mevalonate accumulation 
through upregulation of the TCA cycle following stimulation with LPS.  β-glucan signaling 
notably inhibits the LPS mediated upregulation of immune-responsive gene-1 (IRG-1), the 
enzyme that is responsible for itaconate generation, and stimulates the activity of succinate 
dehydrogenase, leading to increased fumarate production [147].  This is critically important 
as itaconate is known to induce immune tolerance and anti-inflammatory properties in 
human monocytes.  
To date, mechanisms of trained immunity have been primarily studied with regards 
to infection. Recently however,  two studies have highlighted that it may also be possible 
to utilize the induction of trained immunity to kill cancer cells. One of these studies by 
Kalafati et al., describes that pre-treatment of mice with β-glucan induces long-term 




neutrophils that have an anti-tumor phenotype [130]. In the same issue of Cell, another 
paper regarding the use of trained immunity in the setting of cancer appeared, though in 
this paper the authors utilized a novel nano-biologic therapeutic called MTP-HDL. 
Following injection, MTP-HDL was found to target and accumulate in the hematopoietic 
organs of mice and non-human primates. In the BM specifically, MTP-HDL was shown to 
initiate epigenetic modifications in MPPs that are consistent with the initiation of trained 
immunity. For example, they showed that MPPs had higher chromatin accessibility near 
the promoters of genes that regulate TNF-𝛼 and IL-6.  During myelopoiesis, these trained 
myeloid cells were able to initiate anti-tumor effects in a B16F10 subcutaneous model of 
melanoma and not only showed inhibition of tumor growth, but to also showed the 
capability to potentiate the function of immune checkpoint inhibitor therapy [148, 149]. 
These two recent articles are the first descriptions of the use of β-glucan-induced 
trained immunity in the setting of cancer, however both studies utilized subcutaneous 
models of tumors, which do not fully encapsulate the organ-specific features of 
immunosuppression that are present in tumors. Studies over the last three decades have 
consistently shown that the use of subcutaneous tumor models rarely result in the 
occurrence of metastatic disease, and they never result in metastatic disease in the clinically 
relevant organs according to the type of tumor cell used [150-152]. For example pancreatic 
cancer often metastasizes to the liver and lung, however a subcutaneous model of 
pancreatic cancer would not result in metastases to these organs. Additionally, the 
recruitment of anti-tumor immune cells is highly dependent on the vasculature both outside 
and within a tumor, which are controlled by angiogenic processes at the tumor site. There 




of cancer fail to fully recapitulate the true vascular environment of a tumor [153]. 
Additionally, in the setting of pancreatic cancer, for example, pancreatic stellate and 
stromal cells play a critical role in tumor progression, as do resident macrophages Kupffer 
cells in the setting of hepatocellular carcinoma. Subcutaneous models fail to take into 
account these organ-specific drivers of immune-evasion, which can lead to overly 
extrapolated or interpreted conclusions about the efficacy of anti-tumor therapeutics [154]. 
Overall, the use of subcutaneous models of cancer leads to shortcomings in the 
understanding of blood flow, intravascular-tumor cell trafficking, extravasation of tumor 
cells, the architecture of the TME, and the distribution and targeting efficacy of cellular 
and chemical therapeutics [155, 156]. As such, while these initial studies that investigate 
the role of trained immunity in combating cancer are exciting, studies such as the ones 
presented in this dissertation are critical to understanding if the anti-tumor mechanisms of 















THE TRAFFICKING AND BIODISTRIBUTION OF β-GLUCAN 
 
CHAPTER I INTRODUCTION 
Even before β-glucan was identified to be involved in initiating trained innate immune 
responses, β-glucan has been extensively studied for its immunomodulatory properties. 
Understanding the trafficking mechanisms of β-glucan has thus been a focus of β-glucan 
related research. Of all of the routes of administration, orally administered β-glucan has 
been the most extensively studied, however intravenous (IV) and intraperitoneal (IP) 
injections of β-glucan have also been used. Following oral administration, β-glucans move 
into the proximal small intestine where they are phagocytosed by intestinal epithelial cells 
or pinocytic microfold cells (M-cells) which transport β-glucan from the intestinal lumen 
to immune cells within Peyer’s patches [157-159]. Following exposure to β-glucan, 
gastrointestinal macrophages then migrate through the bloodstream toward the lymph 
system, ultimately resulting in trafficking to the bone marrow, spleen and lymph nodes 
[160]. 
IP injection of β-glucan has been less extensively studied than oral administration, 
though there are some studies which show that IP injection has more profound effects on 
immunological activity than does oral administration [161]. Importantly, experiments 




intraperitoneal injection.  Zheng et al. found that following IP administration, β-
glucan was ingested by resident peritoneal macrophages which then trafficked to the lymph 
nodes, thymus and the tumor site in BALB/c mice bearing subcutaneous H22 
hepatocellular carcinomas [162]. Other than this study, there exists sparse detailed 
information about where exactly β-glucan traffics to following IP injection. As such, we 
first sought to identify where β-glucan traffics to following IP administration. In these 
studies we utilize a highly purified form of β-glucan, whole glucan particles (WGP), that 
was purified from  Saccharomyces cerevisiae.  
 
CHAPTER I RESULTS 
To assess the trafficking of particulate -glucan, WGP was tagged with (5-(4,6-
Dichlorotriazinyl) Aminofluorescein) (DTAF), and injected IP into wild-type (WT) 
C57BL/6 mice. Three days following IP administration (3-day WGP), the lung, bone 
marrow, spleen, inguinal and mesenteric lymph nodes, peritoneal cavity cells, and pancreas 
were harvested to detect the presence of DTAF-WGP. While there was some trafficking of 
the DTAF-WGP to the BM, spleen, and mesenteric lymph nodes, and residual DTAF-WGP 
in the peritoneal cavity, the pancreas showed a striking and unexpected presence of the 
DTAF-WGP (Fig 1.1A). In fact, the pancreas appeared bright yellow upon gross visual 
analysis (Fig 1.1B).  To further assess this trafficking and to ensure that the DTAF label 
was not involved in the trafficking mechanism, WGP was radiolabeled with 89Zr and 
injected IP (Fig 1.2A) or incubated for 2 hours with peritoneal macrophages that were then 
injected IP (Fig 1.2B).  Mice were first imaged using a PET/CT scan 48 hours following 




the 89Zr-WGP in the pancreas. A necroscopy was then performed and the radioactive 
signature of each organ was measured. In accordance with the flow cytometry data, 89Zr-
WGP trafficked in large quantities to the pancreas, and was found in lower levels in the 
spleen, liver and intestinal system.  Peritoneal macrophages that were cultured with 89Zr-
WGP and then injected IP had similar though slightly more diversified trafficking than the 
pure 89Zr-WGP, and also accumulated most prominently in the pancreas (Fig 1.2B).  
In an effort to assess the role that the known receptor of WGP played in the trafficking, 
mice lacking the C-type lectin receptor, Dectin-1, (Dectin-1-/- mice) were injected with 
DTAF-WGP and 48 hours later the pancreases were harvested. As compared to WT mice, 
Dectin-1-/- mice showed a 5-fold decrease in the amount of WGP that trafficked to the 
pancreas, as assessed by flow cytometry (Fig 1.3A). 89Zr-WGP was also injected IP into 
WT mice and Dectin-1-/- mice.  As compared to WT animals, there was significantly less 
trafficking of WGP to the pancreas of Dectin-1-/- mice (Fig 1.3B). To ensure that this 
process was in fact -glucan specific, a polystyrene-based latex 3 μm fluorescent particle, 
the same size as a WGP particle, was injected IP and was not found to accumulate in the 
pancreas (Fig 1.4). Finally, as it had been observed that WGP that had been phagocytosed 
by peritoneal macrophages also trafficked to the pancreas upon IP injection of the WGP-
loaded peritoneal macrophages, we also wanted to know whether peritoneal macrophages 
phagocytosed WGP in vivo. To investigate this, DTAF-WGP was injected into mice IP, 
and 4 hours later the peritoneal macrophages were harvested. Confocal microscopy was 
performed to assess if peritoneal macrophages phagocytosed IP injected DTAF-WGP (Fig 
1.5).  This study showed that peritoneal macrophages did phagocytose WGP in vivo, as the 




It appeared form these studies that there was a connection between the peritoneal cavity 
contents and the pancreas. To further understand how WGP trafficked from the peritoneum 
to the pancreas, peritoneal macrophages were harvested from WT mice and stained with 
CFSE. These cells were then adoptively transferred into recipient mice and these mice 
received either IP PBS or WGP.  Mice that received IP WGP displayed more CFSE+ 
macrophages trafficking to the pancreas than those that received PBS (Figure 1.6). This 
highlights that there exists a baseline flux of macrophages from the peritoneum to the 


































Figure 1.1: IP DTAF WGP preferentially accumulates in the pancreas  
(A) DTAF-WGP was injected I.P. and 3 days later different tissues were harvested and 
assessed for the presence of the DTAF-WGP by flow cytometry. (B) Gross anatomical 
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Figure 1.2: Analysis of WGP trafficking using radio-labeled 89Zr-WGP 
(A) WGP was labeled with 89Zr-WGP or (B) peritoneal macrophages were incubated with 
89Zr-WGP and washed, followed by I.P. injection.  PET/CT imaging displays the 
trafficking of the 89Zr-WGP throughout the body after 48 hours. Following the PET/CT 
scan, organs were removed and individually assessed for radioactivity using a gamma 

























































































































































































Figure 1.3: Dectin-1 regulates the trafficking of WGP to the pancreas  
(A) Dectin-1-/- mice or WT mice were injected with DTAF-WGP and the accumulation of 
DTAF-WGP in the pancreas was assessed by flow cytometry. (n=4) (B) Dectin-1-/- mice or 
WT mice were injected with 89Zr-WGP and 48 hours later a PET/CT was used to assess 
the amount in the pancreas. The signal was quantified by reporting the % of injected dose 
(%ID) in the pancreas. (PBS n=4, WGP n=4)  Data are represented as mean ± SEM. *p 






























































































































Figure 1.4:  A polystyrene bead the same size as WGP does not accumulate in the 
pancreas.  
 Fluorescent 3 μm polystyrene beads or PBS were injected IP and 24 hours later the 








Figure 1.5: Confocal microscopy of in vivo phagocytosis of DTAF-WGP  
Mice were injected IP with DTAF-WGP and 4 hours later mice were euthanized, peritoneal 




































Figure 1.6: There is a transient flux of macrophages between the peritoneal cavity 
and the pancreas that is utilized to deliver WGP to the pancreas 
Peritoneal macrophages were harvested from WT mice and incubated with CFSE. These 
cells were then adoptively transferred IP into WT mice. 1 day after transfer of CFSE+ 
peritoneal macrophages, mice were injected with WGP and 24 hours following the 
pancreata were harvested and the presence of CFSE+ macrophages was measured using 





























 CHAPTER I DISCUSSION 
As stated earlier, though the IP administration of β-glucan has been broadly used 
for inducing trained immunity, it has not been well established where it traffics to following 
injection. These studies identify that WGP traffics in small quantities to the lymph system 
and to the bone marrow. It is this trafficking to the bone marrow that likely causes the 
effects of central trained immunity. Surprisingly, we found that WGP also trafficked in 
large proportions to the pancreas which has not been reported before.  It was shown that -
glucan can traffic directly into the pancreas and can also be phagocytosed by macrophages 
which then traffic into the pancreas. While the relationship between the peritoneal cavity 
and the pancreas has not been well defined, studies relating to the pathophysiology of acute 
pancreatitis (AP) have identified that peritoneal macrophages are a principal contributor  
to the inflammatory response in AP [163]. Our imaging data indeed show that peritoneal 
macrophages that phagocytose isotope-labeled WGP primarily traffic to the pancreas. 
Additionally, in an experiment in which CFSE labeled peritoneal macrophages were 
adoptively transferred IP, these macrophages were found at low concentrations in the 
pancreas 24 hours later. Studies on liver injury have further supported this model of a 
dynamic interchange of cells between the peritoneal cavity and solid organs that is 
independent of the circulation [164]. Together this suggests that even in homeostatic 
conditions there exists a basal level of immune cell exchange between the pancreas and 
peritoneal cavity that can be exploited in the setting of particulate -glucan.  
 
While we had identified that macrophages that had phagocytosed WGP traffic to 




traffic to the pancreas due to the visually yellow appearance of the pancreas. To try and 
understand whether peritoneal macrophages were critical in the trafficking of WGP to the 
pancreas, we sought to deplete peritoneal macrophages using liposomal clodronate [165]. 
Despite reports that IP injection of liposomal clodronate results a clean depletion of 
peritoneal macrophages, we found that one day following injection, macrophages were not 
entirely depleted, and further that the immunological makeup of the peritoneal 
compartment was altered to have increased numbers of monocytes and neutrophils. Further 
studies are needed to determine if peritoneal macrophages are requisite for WGP 
trafficking to the pancreas or if naked WGP may traffic there entirely without the assistance 
of them.  
While the impact of -glucan on the immune cells of the pancreas will be explored 
in future sections of this dissertation, this tropism of -glucan to the pancreas carries 
interesting clinical applications given that -glucan has the capability to function as a 
delivery vesicle for cancer therapeutics.   Glucan particles are hollow, and as a result have 
become the subject of research aiming to utilize these properties to employ β-glucan as a 
vesicle to encapsulate, transport, deliver and release therapeutics within the TME, and 
specifically to macrophages. Several groups have already shown that it is possible to load 
β-glucan with different electrostatically-bound compounds, such as siRNA, DNA, protein, 
and small molecules in order to deliver these payloads to macrophages and DCs [166-169]. 
In the setting of pancreatic cancer, where it is not only exceptionally challenging to target 
systemic therapies to the pancreas, but it is also imperative to deliver therapeutics that can 
reprogram the immunosuppressive TME, this poses an attractive treatment strategy. For 




was shown to effectively assemble siRNA into uniformly distributed nanoparticles. On 
administration, these β-glucan containing siRNA nanoparticles were shown to reduce gene 
expression of migration inhibitory factor (MIF), a cytokine and chemokine known to be 
upregulated in the TME in primary macrophages [170]. Upon IV injection, these 
nanoparticles were able to mediate a sustained reduction of MIF in tumor associated 
macrophages (TAMs) in a mouse model of 4T1 mammary cancer [143, 171].  Together 
these studies indicate that this newly characterized trafficking mechanism of β-glucan 
could be exploited to deliver therapeutics directly to the PDAC TME, and future studies 
are underway to investigate this. Ultimately, these data highlight a previously 
uncharacterized, dectin-1 dependent tropism of -glucan to the pancreas that could be 
utilized to deliver therapeutics directly to the pancreas in the setting of cancer.  
 







-GLUCAN TRAFFICKING TO THE PANCREAS INCITES AN INFLUX OF 
INNATE IMMUNE CELLS THAT SHOW A PHENOTYPE OF TRAINED 
IMMUNITY 
 
 CHAPTER II INTRODUCTION 
              Now that we had identified that WGP traffics to the pancreas following IP 
administration, we next turned our attention to investigating whether immune changes in 
the pancreas occurred as a result of the trafficking.  It had previously been shown that IP 
administration of WGP causes an expansion of MPPs and LSKs in the bone marrow. We 
repeated this analysis to confirm that our specific form of particulate yeast-derived -
glucan had the same capability to incite central trained immunity. Unsurprisingly, WGP 
trained mice showed an expansion of Lin-Sca-1+c-Kit+ (LSKs) and CD48+CD150- (MPPs) 
7 days after injection in our model of trained immunity indicating the successful induction 
of central trained immunity (Fig 2.1A+B). Additionally, DTAF-WGP was found to traffic 
in small proportions to the bone marrow (Fig 2.1C). These results confirmed that the WGP 
used in our experiments stimulates a typical program of trained immunity. While this 
expansion has been noted before, the presence of trained cells within the pancreas has not 
been described before. Thus, the trafficking of WGP to the pancreas also caused us to 
question not only how the immune cell populations change, but also whether cells in the 




CHAPTER II RESULTS 
Trafficking of immune cells into the pancreas 
After discovering that -glucan displays tropism toward the pancreas, it was also 
observed that the immune landscape of the pancreas was significantly altered following 
WGP treatment. Arrival of WGP to the pancreas was accompanied by a distinct influx of 
CD11b+ myeloid cells to the pancreas by day 3, some of which had phagocytosed WGP 
(Fig 2.2A). This finding led us to examine how overall immune populations of the pancreas 
are impacted following IP WGP treatment. As it has been previously observed that the 
immune changes associated with trained immunity in the BM are most pronounced one 
week following exposure to -glucan [131], the immune profile of the pancreas was 
examined in mice treated with a 3 m polystyrene microparticle or WGP 7 days following 
IP injection. First, it was observed that there was about a 10-fold increase in the overall 
percent of CD45+ immune cells in the pancreas after WGP treatment (Fig 2.2B).  There 
was an observed increase in the absolute number of CD45+ immune cells (Fig 2.2C). A 3 
m polystyrene microparticle control did not have such effects (Fig 2.2D), indicating that 
this immune cell influx is WGP specific.  To further classify which cell types were 
responsible for this expansion of the CD45+ immune population, the relative percent (Fig 
2.2B) and absolute number (Fig 2.2C) of myeloid cells (CD11b+), T-cells (CD3+), B-cells 
(CD19+), and NK cells (NK1.1+) were evaluated.  The cumulative changes in the pancreas 
are represented by pie charts which demonstrate that the expansion of the myeloid 
compartment is responsible for the relative decrease in the percentage of other cell 
populations and the overall increase in the CD45+ population following WGP treatment 




We next investigated whether this influx of CD11b+ immune cells was transient, so the 
percent of overall CD45+ cells and CD11b+ cells in the pancreas following IP injection was 
measured at 7,10, 18 and 30 days. While the percent of CD11b+ cells peaked at day 7, the 
percent of CD45+ cells appeared to peak at day 10 which may indicate that following influx 
of CD11b+ cells to the pancreas, an influx of other immune cell types may follow, though 
it was not investigated what type of cells these may be. The percent of immune cells in the 
pancreas decreased to basal levels by day 30, demonstrating that this influx is transient (Fig 
2.3A). Within the myeloid compartment, we observed that the percent (Fig 2.3B) and 
absolute numbers (Fig 2.3C) of macrophages (F4/80+), monocytes (Ly6C+), and 
neutrophils (Ly6G+) were all increased. The influx of immune cells into the pancreas was 
shown to be dependent on the dose of WGP injected, where higher doses of WGP were 
associated with increased influx of overall CD45+CD11b+ myeloid cells and 
CD45+CD11b+F4/80+ macrophages (Fig 2.4). We also wanted to ensure that this observed 
phenomenon was not specific to C57BL/6 mice, and so investigated whether other 
commonly used  mouse strains, such as BALB/c mice, also showed an influx of immune 
cells into the pancreas following WGP injection.  BALb/c mice also showed a 15 fold 
increase in CD45+ cells in the pancreas after WGP injection (Figure 2.5).  
As pancreatitis and the destruction of pancreatic islets are associated with immune cell 
infiltration of the pancreas, H+E of the pancreas was performed to assess the integrity of 
pancreatic islets 7 days after WGP administration (Fig 2.6A). Serum amylase, a diagnostic 
marker of pancreatitis, was also measured in WGP vs PBS-treated mice 7 days following 
injection (Fig 2.6B). Neither the islets nor the serum amylase were adversely impacted by 




this mechanism does not cause pancreatic destruction. Further, following WGP treatment 
mice were monitored for up to 3 months, and no morbidities or mortalities were associated 
with WGP treatment.  
As the islets were not adversely impacted by the influx of immune cells, we wondered 
where the immune cells were located. H+E imaging of PBS and WGP treated mice showed 
that the cellular infiltrates appeared to be located in a layer around the pancreas that was 
rich in adipose tissue, and were starkly increased in WGP treated mice (Fig 2.7A+B). This 
layer was connected to the pancreas and was identified as being a part of the serosa capsule 
that surrounds the pancreas.  
 
Trained Immunity in the Pancreas 
To investigate whether the cells found to infiltrate the mouse pancreas following WGP 
treatment displayed a phenotype of trained immunity, we used a standard training protocol 
in which mice were treated with WGP or PBS and 7 days later the pancreas were harvested, 
processed into a single cell suspension, and then restimulated with LPS. TNF- production 
has been used as a surrogate marker to evaluate the trained response. Overall CD11b+ 
myeloid cells, CD11b+F4/80+ macrophages and CD11b+Ly6C+ monocytes were all shown 
to produce more TNF- due to prior exposure to WGP, as assessed by the percent of TNF-
+ cells and the MFI (Fig 2.8). To further assess these findings, CD11b+ cells were sorted 
from the pancreas of these mice and restimulated ex-vivo with LPS, and the TNF- and IL-
6 levels in the supernatants were measured by ELISA. As compared to CD11b+ cells from 
PBS mice, cells from WGP-trained mice that were restimulated with LPS produced 




CD11b+ cells were trained. These results were further confirmed using RT-PCR, where 
pancreatic CD11b+ cells sorted from PBS or WGP-trained mice were shown to produce 
more TNF-, IL-6, iNOS and less IL-10 due to WGP treatment (Fig 2.9B). Together these 
findings indicate that not only does WGP incite a trained phenotype in the cells that traffic 
into the pancreas, but that they also have an overall pro-inflammatory phenotype.  
Some reports have indicated that the microbiota of mice can play a role in the induction 
of trained immunity [172, 173]. The microbiome of mice can be drastically different 
between facilities and breeding colonies, and so we wanted to confirm that the induction 
of trained immunity in the pancreas was not dependent on factors related to the microbiome 
of the mice in our facility [174-176]. To investigate this, germ-free mice housed in the 
germ-free facility at the University of Louisville were injected IP with WGP and the 
induction of trained immunity in pancreatic myeloid cells was assessed (Fig 2.10).  
Myeloid cells from WGP-treated germ-free mice did display increased production of 
TNF as compared to PBS-treated mice, indicating that while the microbiota may play a 
role in trained immunity, it was not a critical factor in this model.  
 
RNA-Seq and CyTOF Analysis of WGP-induced influx of myeloid cells   
RNA sequencing (RNA-Seq) was then performed on FACS sorted CD45+CD11b+ cells 
7 days following PBS or WGP training to obtain an unbiased and comprehensive 
characterization of myeloid populations in the pancreas.  A total of 1459 Differentially 
Expressed Genes (DEGs) were discovered, with 661 upregulated and 798 genes 
downregulated in the WGP-trained setting (Fig 2.11A). In accordance with the observed 




monocyte chemotaxis, macrophage migration, mononuclear cell migration, and myeloid 
leukocyte migration (Fig 2.11B) were all significantly enriched. Gene set enrichment 
analyses (GSEA) further confirmed previously investigated upregulations in pathways 
related to TNF- cytokine production, IL-6 production, and nitric oxide production (Fig 
2.11C).  Additionally, Reactome pathways CLEC7A dectin-1 signaling and C-type lectin 
receptor pathways were significantly enriched, further corroborating the Dectin-1 
involvement in this process (Fig 2.11D).  
Considering that the myeloid population was observed to be responsible for the 
expansion of the CD45+ population and that myeloid cells are a diverse population, CyTOF 
analysis was performed on pancreata from mice treated with PBS or WGP 7 days prior. 
Cell populations within the pancreas were identified and compared between treatment 
groups; t-SNE plots indicate that following WGP treatment, numerous new populations of 
myeloid cells are present in the pancreas due to WGP treatment (populations 11, 2, 6, 8, 9, 
12, 13, 14, 15, and 17) which though heterogenous were characteristically defined by the 
surface expression of Ly6C, F4/80, MHCII, CCR2, CD80, CD86 and PD-L1, indicative of 
activated inflammatory macrophages and monocytes. These populations are highlighted 
within the black circle (Fig 2.12, Fig 2.13). viSNE plots gated on the CD11b+ population 
showed a distinct expansion of monocytes and macrophages, with additional increases of 
the Dendritic Cell (DCs), neutrophil, and NK populations after WGP treatment (Fig 
2.14A). Additionally, these analyses highlight that following WGP training and LPS 
restimulation, TNF was primarily produced by macrophages and monocytes, IL-6 and 
iNOS were primarily produced by macrophages, Granzyme-B was produced by NK-cells 




reveals that while many cell populations are changed due to WGP treatment, the primary 
cells trained by WGP, as assessed by increased TNF expression, are macrophages and 
monocytes and that there is not a singular cell type responsible for the phenotype of the 
trained immunity that was observed.  
 
Myeloid cells in the pancreas are trained independently of adaptive immune 
responses 
To assess whether this phenomenon of myeloid cell influx and activation was 
dependent upon other immune populations or driven entirely by the myeloid cells 
themselves, we depleted specific immune populations and observed the trained phenotype. 
Anti-CD4 and anti-CD8 mAbs were used alone and in combination to deplete T-cells, the 
efficiency of depletion was assessed (Fig 2.15A), and the trained phenotype of myeloid 
cells was observed (Fig 2.15B+C). NK cells were depleted using mAb PK136, the 
depletion efficiency was evaluated (Fig 2.16A) and the trained phenotype was observed 
(Fig 2.16B). In these depletion conditions, myeloid cells were still observed to be trained 
by WGP. The trained phenotype was also assessed in NSG mice which lack B-cells, T-
cells, and NK cells (Fig 2.17). These mice still showed a clear phenotype of trained 
immunity. We also depleted neutrophils using Ly6G mAb. Despite depletion of 
granulocytes, we still observed WGP-induced training in the CD11b+ myeloid 
compartment (Fig 2.18). Taken together, our data support that the infiltrating myeloid cells 
in the pancreas are trained by -glucan without the assistance or influence of adaptive 





A single-cell RNA sequencing reveals specific populations of pro-inflammatory 
macrophage/monocytes that traffic to the pancreas upon -glucan treatment 
To gain a more in-depth understanding of the cell populations present in the pancreas 
after WGP treatment, a single-cell RNA sequencing (scRNA-Seq) was performed on sorted 
CD45+ cells from PBS-treated mice and mice treated with WGP three (3-day WGP) and 
seven days prior (7-day WGP). Two dimensional UMAP representation of 11,132 cells 
aggregated from three samples (PBS=4213, 3-day WGP=3757, 7-day WGP=3244) with 
clusters resulting from k-nearest neighbors and Louvain algorithms partitioned into 19 
distinct clusters (Fig 2.19A+B). The relative frequency of each cluster within each 
experimental group was assessed. Here, significant increases in the frequency of clusters 
3,4, and 10 were observed by day 7 after WGP treatment, along with a near disappearance 
of cluster 5 (Fig 2.19C). The relative frequencies of several other populations were also 
shown to decrease over time. However, this apparent trend is likely due to the relative 
increase in frequency of other populations. Overall, clusters 3,4,10 and 5 appear most 
significantly altered due to WGP treatment (2.19C) 
The populations noted previously to be most significantly altered over time due to WGP 
treatment were part of the myeloid compartment, as identified by CSF1R expression (Fig 
2.20A+B). As these data along with previous findings suggests that myeloid populations 
drive the immune changes associated with WGP treatment, the dynamic CSF1R+ clusters 
3,4,10 and 5 were investigated in more detail as shown by UMAP and violin plots (Fig 
2.21A+B) and dot plots representing the top 12 marker genes by average Z-score for each 
cluster (2.22A). Cluster 5, which was present in PBS mice but virtually disappeared after 




TNFAIP2, indicating that these cells are resident macrophages [177, 178]. This cluster also 
notably expressed MAF and APO which are both related to M2 macrophage polarization 
[179-181]. Cluster 19 was largely unchanged over time so was not described in more detail, 
but exhibited an expression profile similar to cluster 5, and thus also represents a subset of 
tissue resident macrophages. Cluster 10 was characterized as ITGAMHiADGRE1HiLyz2Hi 
H2-Ab1Int Ly6C2- with notable expression signatures of ARG1 and FABP. Clusters 3 and 4 
share general phenotypic characterization as ITGAMInt ADGRE1Int Lyz2Hi H2-Ab1Int 
Ly6C2Hi CCR2Hi, which suggests that both are subsets of infiltrating 
monocytes/macrophages. Cluster 4 had notable expression of Chil3 and Plac8, which 
together have been identified by another group to identify Ly6Chi infiltrating macrophages 
in the kidney [182].  Finally, cluster 3, which was absent in naïve mice and showed the 
greatest increase in relative frequency among all clusters following WGP treatment 
expressed substantial signatures of TNFAIP2, IL1B, SOD2, and PRDX5, indicating a 
strongly pro-inflammatory phenotype. Cluster 3 was thus identified as inflammatory 
infiltrating monocytes/macrophages. Interestingly, within the myeloid subset, the 
populations shown to increase due to WGP treatment are the only populations to express 
TNFAIP2, indicating that our previous use of TNF as a surrogate marker of trained 
immunity was accurate.  
To further characterize the activation status of each of the four dynamic myeloid 
clusters, dot plots were constructed to show the relative expression of genes associated with 
a pro-inflammatory status and an anti-inflammatory status (2.22B). Clusters 3 and 4, the 
infiltrating monocytes/macrophages, were shown to be pro-inflammatory, the resident 




intermediate phenotype. In agreement with previous CyTOF and flow cytometry data, this 
scRNA-Seq data further characterize the newly identified pro-inflammatory monocytes 




































Figure 2.1: IP WGP traffics to the bone marrow and causes an expansion of myeloid 
progenitor cells  
The bone marrow of mice injected with IP WGP or PBS was analyzed for (A) Lin-Sca-1+c-
Kit+ (LSKs) and  (B) CD48+CD150- MPPs 7 days after injection. (C) DTAF WGP was 
injected IP and 3 days later the bone marrow was assessed for the presence of WGP. Data 






















Figure 2.2: IP WGP causes an influx of CD11b+ myeloid cells into the pancreas  
(A) WT mice were treated with I.P. DTAF-WGP and 3 days later the percent of 
CD11b+DTAF+ cells in the pancreas were identified with flow cytometry. Cells were 
previously gated on CD45+. (B) 7 days after I.P. PBS or WGP injection (7-day WGP), the 
percent of CD45+ cells in the pancreas were identified. The percent of CD11b+, CD3+, 
CD19+ and NK1.1+ cells within the CD45+ population were also measured. (C) The 
absolute number of CD45+ immune cells, NK1.1+ NK cells, CD19+ B-cells, CD3+ T-cells, 
CD11b+ myeloid cells in PBS and 7-day WGP trained mice. (D) 3 μm polystyrene beads 
or PBS were injected IP and 7 days later the percent of CD45+ cells in the pancreas were 
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immune cell population between the PBS vs 7-day WGP treatment setting. Data are 






































Figure 2.3: A transient influx of diverse myeloid cell subtypes occurs after WGP 
treatment  
(A) WT mice were injected with WGP and the percent of CD45+ and CD45+CD11b+ cells 
were measured 7, 10, 18, and 30 days later. These were compared to PBS treated mice. (B) 
Gated on the pancreatic CD45+CD11b+ population, the percent of F4/80+ (macrophages), 
Ly6C+ (monocytes) and Ly6G+ (neutrophils) were measured using flow cytometry. (C) 
The absolute number of CD11b+F4/80+ macrophages, CD11b+Ly6C+ monocytes, and 
CD11b+Ly6G+ neutrophils in PBS and 7-day WGP trained mice. Data are represented as 






























































































































































































Figure 2.4: The trafficking of immune cells into the pancreas is dose dependent  
The percent and absolute number of CD45+, CD45+CD11b+ and CD45+F4/80+ cells in PBS 






Figure 2.5: The influx of immune cells is not C57BL/6 specific  
Balb/c mice were given IP WGP and 7 days later the pancreata was harvested and the 



















































































































































































Figure 2.6: The WGP-driven influx of immune cells does not harm the pancreas 
(A) A representative section from H+E imaging of the pancreas from PBS and 7-day WGP 
trained mice. (B) The levels of amylase in the serum of PBS and 7-day WGP trained mice. 





















































Figure 2.7: H+E imaging of PBS and WGP treated pancreases  
(A) Mice were treated with PBS or WGP and 7 days later the pancreases were harvested 
and analyzed to determine the location of the immuneological influx. (A) PBS v WGP 
treated pancreases highlighting the fatty viscera that appears to be the target of immune 























Figure 2.8: Myeloid cells in the pancreas display features of trained immunity  
Mice were trained with PBS or WGP. 7 days later mouse pancreas were harvested and 
single-cell suspensions were restimulated with LPS. TNF production in CD11b+, 
CD11b+F4/80+, and CD11b+Ly6C+ cells were measured using intracellular staining by 
flow cytometry. Data are represented as mean ± SEM. ns= not-significant; *p <.05, **p 






























































































Figure 2.9: Enriched CD11b+ pancreatic cells show a phenotype of trained immunity  
(A) 7 days after PBS or WGP training, the CD45+CD11b+ population was enriched using 
FACS sorting. Cells were plated and restimulated with PBS or LPS for 24 hours and the 
TNF and IL-6 in the supernatant were measured using an ELISA. (B) Pancreatic CD11b+ 
cells from PBS and WGP-trained mice were sorted using FACS and RT-qPCR was done 
to quantify TNF, IL-6, iNOS and IL-10 mRNA expression levels. Data are represented 























































































































Figure 2.10: the induction of trained immunity in germ-free mice  
Germ-free animals bred and maintained in the university of Louisville germ-free animal 
facility were injected with WGP and 7 days later the pancreatic myeloid cells were 
restimulated with LPS and the production of  TNF was assessed. Data are represented as 




































Figure 2.11: RNA-Seq analysis of PBS versus WGP treated pancreatic CD11b+ cells  
Mice were trained with PBS or WGP and 7 days later the CD45+CD1b+ populations were sorted 
and RNA-Seq analysis was performed (PBS n=3, WGP n=3). (A) The distribution of p values 
(-log10(p value)) and fold changes (log2 FC) of differentially expressed genes in WGP vs PBS 
trained cells are shown in a volcano plot.  (B-D) Enrichment plots generated by Gene Set 
Enrichment Analysis (GSEA) for genes related to  (B) monocyte chemotaxis, mononuclear cell 
migration, macrophage migration, leukocyte migration, leukocyte chemotaxis, and leukocyte 
migration, (C) TNF and IL-6 production, and  (D) Dectin-1 signaling in CD11b+ cells from 
7-day WGP-trained as compared to PBS mice. 
A 





FDR q-Val: 0.012 FDR q-Val: 0.012 
FDR q-Val: 0.0175 FDR q-Val: 0.024 
GO_Monocyte Chemotaxis  
FDR q-Val: 0.027 




FDR q-Val: 0.012 
FDR q-Val: 0.005 
GO_+ regulation of TNF   




 Dectin-1 Signaling 
Reactome_C-Type 
 Lectin Receptors (CLRS) 



















Figure 2.12: Characterization of the pancreatic CD11b+ population using CyTOF 
 t-SNE plots of the CD11b+ population in mice trained with PBS or WGP 7 days prior and 
analyzed with CyTOF (PBS n=3, WGP n=3). The black circle highlights new cell 














Figure 2.13: Heatmap of the median scaled expression of the CyTOF markers in each 













































Figure 2.14: Functional characterization of pancreatic CD11b+cells sing CyTOF 
(A) viSNE plots of CD11b+ pancreatic cells in PBS and 7-day WGP trained mice, made 
from CyTOF data, highlighting  the specific expression of Ly6C, F4/80, CD11c, Ly6G and 
NK1.1 in order to indicate the relative location of the major immune-cell subsets and 
changes between the PBS and WGP treatment group. (B) viSNE plots of CD11b+ 
pancreatic cells in PBS and 7-day WGP trained mice, made from CyTOF data, showing 
the expression of TNF, IL-6, Granzyme-B, iNOs and IFN. 
 
 























































Figure 2.15: Training of pancreatic myeloid cells is not dependent on T-cells   
(A) Representation of the T-cell depletion efficiency in the spleen of anti-CD-4 and cnti-
CD-8 mAbs used in vivo. (B+C) Mice depleted of CD4+ T-cells, CD8+ T-cells or both 
CD4+ and CD8+ T-cells and WT mice were given I.P. WGP and 7 days later the pancreatic 
cells from these mice and WT mice treated with PBS were restimulated with LPS. TNF 
production in the CD11b+ cells was measured by flow cytometry. Summarized data is 
























































































Figure 2.16: Training of pancreatic myeloid cells is not dependent on NK cells   
(A+B) NK-cell depleted mice and WT mice were treated with PBS or WGP and 7 days 
later the pancreatic cells from these mice were restimulated with LPS. TNF production 
in the CD11b+ cells was measured by flow cytometry. Summarized data is shown. Data 



















































































Figure 2.17: Adaptive immune responses to not involved in the training of pancreatic 
CD11b+ myeloid cells  
NSG mice were injected with PBS or WGP and 7 days later pancreatic cells were 
restimulated with LPS. TNF production in the CD11b+ cells was measured by flow 
cytometry. Representative and summarized data are shown.  Data are represented as mean 













































































Figure 2.18: Training of pancreatic myeloid cells is not dependent on granulocytes  
(A) The depletion efficiency of an anti-ly6G mAb and its isotype control (anti-rat IgG2a) 
was assessed in the mouse pancreas. (B)  Mice treated with the anti-Ly6G mAb and isotype 
control were given either PBS or WGP and 7 days later pancreatic cells were restimulated 
with LPS. TNF production in the CD11b+ cells was measured by flow cytometry. 
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Figure 2.19: Single-cell RNA-Seq showing the immune cell phenotype 3 and 7 days 
following IP WGP 
CD45+ cells from the pancreas of mice treated with PBS or WGP 7 days and 3 days prior 
were sorted and scRNA-Seq was performed. (A)Two dimensional UMAP representation 
of 11,132 cells aggregated from the three experimental samples with 20 unique clusters 
resulting from k-nearest neighbors and Louvain algorithms. (B) Heatmap of expression of 
aggregated marker genes for all clusters. (C) Bar graphs showing the relative frequency of 































































































Figure 2.20:  scRNA-Seq identifies CSF1R+ myeloid populations that are increased 
following WGP treatment  
CD45+ cells from the pancreas of mice treated with PBS or WGP 7 days and 3 days prior 
were sorted and scRNA-Seq was performed. (A) UMAP dimension reduction of PBS 
(blue), 3-day WGP (green) and 7-day WGP (red) samples shown individually. The portion 
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Figure 2.21: Classification of differentially regulated myeloid populations in the 
pancreas using scRNa-Seq   
CD45+ cells from the pancreas of mice treated with PBS or WGP 7 days and 3 days prior 
were sorted and scRNA-Seq was performed. (A) Single-cell expression distributions across 
clusters identified as myeloid cells for select genes related to myeloid phenotyping. (B) 
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Figure 2.22: Characterization of differentially regulated myeloid populations in the 
pancreas using scRNA-Seq   
CD45+ cells from the pancreas of mice treated with PBS or WGP 7 days and 3 days prior 
were sorted and scRNA-Seq was performed. (A) Dot plot of the top 12 enriched genes in 
cluster 3,4,5 and 10 showing the average expression level and percentage of cells 
expressing select genes. (B) Dot plots showing the enrichment of selected genes associated 
with pro-inflammatory (green) and anti-inflammatory (red) immune responses across 
clusters 3,4,5 and 10. The average expression level is displayed as z-scores computed 















CHAPTER II DISCUSSION 
 
 
 While it was expected that WGP trafficking to the pancreas would result in 
immunological changes to the resident populations there, it was surprising to observe such 
a profound influx of innate immune cells to the pancreas. DTAF-WGP studies demonstrate 
that while macrophages that have phagocyted WGP traffic to the pancreas, there also exists 
a population of CD11b+ myeloid cells that traffic to the pancreas that have not 
phagocytosed WGP. It is likely that the trafficking of peritoneal macrophages that have 
phagocytosed WGP to the pancreas incites the production of cytokines and chemokines 
that then recruit additional myeloid cells  there. Despite the presence of these myeloid cells, 
importantly, both short-term and long-term observation of mice show that this WGP-driven 
influx of immune cells into the pancreas does not cause morbidity or mortality in mice. 
Serum amylase levels were not increased, which would be indicative of pancreatic 
destruction or pathological pancreatitis.   
Preliminary H+E imaging of WGP-treated pancreases showed an accumulation of 
immune cells in a fatty layer attached to the pancreas. We hypothesized this to be part of 
the greater omentum, a fold of visceral peritoneum that attaches to the pancreas in mice. 
The greater omentum has been known to have immunogenic properties and has also been 
shown to be a destination of activated peritoneal macrophages[183, 184]. To explore this 
further we performed omentectomies on mice where we detached the omentum from the 
pancreas and removed the distal fold of the tissue. After one week had passed, we injected 




trafficking to the pancreas. Despite the lack of a greater omentum, DTAF-WGP still 
trafficked to the pancreas and CD11b+ myeloid cells still accumulated in the pancreas, 
though the inflammation caused as a result of the procedure made a full analyses of the 
pancreas challenging. Kubes et al had reported that in the setting of liver injury, large 
GATA6+ peritoneal macrophages take an avascular route of migration to the liver where 
they traffic to and through the visceral endothelium that covers the liver within one hour 
following the induction of sterile injury[164, 185]. These findings highlight a non-vascular 
recruitment of immune cells to visceral organs that could be related to the influx of immune 
cells observed in this model.  While chapter 3 of this dissertation will address some of the 
signaling mechanisms involved in recruiting innate immune cells to the pancreas, it still 
remains unknown why WGP traffics to the pancreas or why macrophages that have 
phagocytosed WGP also traffic there.  
Following WGP treatment, myeloid cells within the pancreas were shown to exhibit a 
trained phenotype upon LPS restimulation that was not dependent on any adaptive immune 
populations. More in depth investigations using CyTOF, RNA-Seq and scRNA-Seq data 
together confirmed that WGP led to the upregulation in a number of genes associated with 
trained immunity and enhanced effector function.  4 myeloid populations exhibited 
noteworthy dynamic behavior following WGP treatment, several of which have not been 
previously identified in the mouse pancreas. First, cluster 5 which was 
ITGAMIntADGRE1HiLyz2HiH2-Ab1HiLy6C2- was present in PBS mice and virtually 
disappeared following WGP treatment. Their presence in the pancreas of WT mice along 
with high F4/80 expression, and low Ly6C expression designate cluster 5 as resident 




polarization [186]. Resident macrophages of the pancreas are known to exhibit M2 
polarization as these cells are involved in would healing and tissue repair [187]. Cluster 
10, defined by the expression of ITGAMHiADGRE1HiLyz2Hi H2-Ab1Int Ly6C2- is absent in 
PBS treated mice and appears at day 3 after WGP treatment. This population has a similar 
expression profile to cluster 5 (ITGAMIntADGRE1HiLyz2HiH2-Ab1HiLy6C2-), the 
alternatively activated M2 resident macrophage population, though cluster 10 appears to 
skew more towards an M1 classically activated macrophage phenotype. The reciprocal 
increase in cluster 10 and decrease in cluster 5 at days 3 and 7 post-WGP treatment along 
with a lack of CCR2 expression suggest that cells in cluster 10 could be resident 
macrophages that have been trained by the -glucan, and subsequently adopts an activated 
phenotype, thus forming a new cluster. While further studies are warranted to investigate 
whether resident macrophages in the pancreas are impacted by WGP, given the relative 
disappearance of the resident population following WGP treatment it is likely that this is 
the case.   
Cluster 3 and 4 were both classified as types of inflammatory macrophages/monocytes 
based on the expression of ITGAMInt ADGRE1Int Lyz2Hi H2-Ab1Int Ly6C2Hi along with high 
expression of TNFAIP2 and CCR2.  Cluster 3, a novel pancreatic population which exhibits 
the most evident features of trained immunity is absent in naïve mice and becomes the 
cluster with the highest relative frequency by day 7 after WGP administration.  Recent 
studies into the mechanism of trained immunity show that after -glucan administration, 
monocytes from trained HSCs in the bone marrow can migrate to peripheral organs where 
they become monocyte-derived macrophages that not only are longer lived than typical 




phenotype, the high expression of CCR2, and that the majority of the influx of this 
population happens more than 3 days following WGP administration, we speculate that 
cluster 3 and 4 may represent such BM-derived cells that are directed to the pancreas 
shortly after WGP arrives there. This development of peripheral trained immunity has been 
described in several tissues but has not been previously identified to exist in the pancreas 













WGP-INDUCED TRAFFICKING OF IMMUNE CELLS TO THE PANCREAS IS 
CCR2 DEPENDENT  
 
CHAPTER III INTRODUCTION 
After discovering that the two most prominent cell populations to traffic to the pancreas 
due to WGP treatment were macrophage/monocyte populations that highly expressed 
CCR2, we wanted to know whether CCR2 signaling may be responsible for this influx of 
cells into the pancreas. CCR2 is known to be highly expressed on blood monocytes, and 
CCR2-/- mice are known to have increased numbers of monocytes in the BM, suggesting 
that CCR2 expression is critical to monocyte egress from the BM [192]. Monocyte 
chemoattractant protein-1 (MCP-1), also known as CCL2, is the primary ligand for CCR2, 
and is expressed by a variety of cell types including endothelial cells, smooth muscle, 
fibroblasts [193, 194], tumor cells  [195] and myeloid cells.  CCL2 is best known as a 
chemoattractant, where its expression induces monocyte adhesion to the vascular 
endothelium, extravasation through blood vessels and chemotaxis to tissues with high 
CCL2 concentrations [196]. Overall, CCL2 expression is critical in both recruiting 
circulating monocytes from the periphery to a site of inflammation, and in mobilizing 
CCR2+ monocytes from the bone marrow [192]. Given the observed recruitment of 




we hypothesized that CCR2/CCL2 signaling may be important in the recruitment of 
these cells. 
 
CHAPTER III RESULTS  
 
To investigate the mechanism of myeloid cell recruitment to the pancreas, RNA-Seq 
data was used to characterize chemokines and cytokines whose expression was 
significantly upregulated upon WGP treatment (Fig 3.1A), and scRNA-seq data was used 
to investigate which cells might be responsible for this upregulation (Fig 3.1B).While 
several chemokines and cytokines were upregulated, our observation of macrophage and 
monocyte influx into the pancreas piqued a specific interest in CCR2 due to its involvement 
in monocyte and macrophage recruitment and in monocyte egress from the bone marrow 
[197-199].   CyTOF data also showed a prominent increase in CCR2 positive cells after 
WGP treatment (Fig 3.2A) and scRNA-Seq showed a distinct expression of CCR2 in 
clusters 3 and 4, which were the two populations that showed the most distinct phenotypes 
of trained immunity (Fig 3.1B). Additionally, 24 hours post-WGP treatment, whole 
pancreatic lysates showed a 30-fold increase in CCL2, which is the ligand for CCR2 and 
is involved in mediating monocyte chemotaxis (Fig3.2B)    
While RNA-Seq data had shown a clear signature of immune cell recruitment and 
trafficking, these data had also indicated that WGP upregulated proliferation of leukocytes 
and mononuclear cells (Fig 3.3A). To investigate whether the CCR2+ myeloid cells were 
proliferating once they reached the pancreas, WT mice were treated with WGP or PBS and 
7 days later pancreatic cells were assessed for Ki67 expression. Cells were first gated on 




what percent of the proliferating cells were CCR2+ myeloid cells.  Following WGP 
treatment there was an increase in overall proliferating cells (Fig 3.3B) and a large percent 
of these proliferating cells were CD11b+CCR2+ (Fig 3.3C). We then investigated the 
contribution of CCR2+ cells to the trained phenotype. 7 days after in vivo treatment with 
PBS or WGP, CCR2+ and CCR2– populations were measured for trained response (Fig 
3.4). This data indicated that the majority of cells trained following WGP treatment were 
CCR2+. To further examine the role of CCR2 in -glucan trained monocytes/macrophages, 
CCR2-/- mice were trained with WGP -glucan. CCR2-/- mice did not undergo an influx of 
CD45+ (Fig 3.5A) or CD45+CD11b+ myeloid cells (Fig 3.5B) into the pancreas, and did 
not show a trained response as revealed by TNF- production (Fig 3.5C). This data 
indicates that CCR2 plays a critical role in the migration of innate immune cells to the 
pancreas and in the induction of peripheral trained immunity in the pancreas.   
As previously noted, CCR2 is important for early recruitment of monocytes, but less 
so for late recruitment [200].  Thus far, we had also observed that at 7 days following WGP 
training, CCR2 was critical to the recruitment of trained myeloid cells to the pancreas.  We 
next examined whether this influx occurred at an early time point upon WGP training and 
whether the CCR2+ myeloid cells were recruited to the pancreas. To this end, mice were 
treated with PBS or WGP and pancreatic tissues were analyzed 24 and 48 hours later. 
Surprisingly, as early as 24 hours after WGP training, increases in CD45+ (Fig 3.6A), 
CD11b+ (Fig 3.6B), F4/80+ (Fig 3.6C), Ly6C+ (Fig 3.6D) and CD11b+CCR2+ (Fig 3.6E) 
cells were observed. Additionally, it was shown that these myeloid cells were also trained 




between these results and previously observed phenotypes of trained immunity which 
usually are not initiated until at least 3 days following training (Fig 3.6F).  
 





















Figure 3.1: Chemokines and cytokines upregulated by WGP treatment 
(A) Heatmap of chemokines and cytokines that were upregulated in 7-day WGP treated 
CD11b+ cells based on RNA-Seq data (B) scRNA-Seq data showing a UMAP of the 
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Figure 3.2: CCR2/CCL2 signaling is increased due to WGP treatment  
(A) viSNE plot of the CD11b+ pancreatic population in PBS and 7-day WGP-trained mice, 
highlighting the expression of CCR2. Images made with CyTOF data. (B) CCL2 


























































Figure 3.3: Proliferation of CCR2+ cells in the pancreas  
 
(A) GSEA generated enrichment plots of genes related to leukocyte proliferation in 
CD11b+ pancreatic cells from 7-day WGP-trained as compared to PBS mice. (F) 
Summarized data of the percent of CD45+ pancreatic cells that are Ki67+ in PBS and 7-
day WGP-trained mice. (B) Cells were first gated on the CD45+Ki67+ population. Plots 
show the percent of the CD45+Ki67+ proliferating pancreatic cells that are CD11b+CCR2+  








































































Figure 3.4: CCR2+ cells in the pancreas are trained due to WGP  
Pancreatic cells from PBS and 7-day WGP-trained mice were restimulated with LPS and 
the percent of CCR2 positive and negative cells producing TNF was measured in each 
condition. Cells were first gated on the CD45+CD11b+ subset. Data are represented as mean 







































































































Figure 3.5: cellular influx and training of pancreatic innate myeloid cells do not occur 
in CCR2-/- mice  
(A-C) WT and CCR2-/- mice were treated with PBS or WGP and the percent of (A) CD45+ 
cells in the pancreas (B) and the percent of CD45+ cells that were CD11b+ was assessed. 
(C) The percent of CD45+CD11b+ cells producing TNF. Data are represented as mean ± 





















































































































Figure 3.6: Pancreatic myeloid cells 
are trained by 24 and 48 hours post-
WGP 
Mice were treated with WGP 24 hours 
or 48 hours before euthanization and the 
percent of (A) CD45+, (B) percent of 
CD45+ cells that were CD11b+, (C) 
percent of CD45+CD11b+ cells that were 
F4/80+ and (D) the percent of 
CD45+CD11b+ cells that were Ly6C+ 
cells were measured and compared to 
that of a PBS treated mouse. (E) 
Pancreatic cells from PBS and 24 and 
48 hour WGP treated mice were gated 
on the CD45+ population and the 
percent of these cells that were 
CD11b+CCR2+ was assessed. (F) 
Pancreatic cells from PBS and 24 and 
48 hour WGP treated mice were 
restimulated with LPS and the production of TNF was measured. All analyses were done 
by flow cytometry and representative and summarized data are shown. Data are represented 







CHAPTER III DISCUSSION 
 
24 hours following the administration of WGP, CCL2 levels in whole pancreatic lysates 
were found to be increased by 30 fold.  Accordingly, we show that the recruitment of 
immune cells and the establishment of this peripheral trained immunity in the pancreas is 
dependent on CCR2 signaling. We also show that CCR2+ cells account for the majority of 
cells that are trained following WGP treatment. Together this suggests that WGP 
trafficking to the pancreas upregulates CCL2 signaling which then is sufficient to recruit 
CCR2+ trained cells from the bone marrow to the pancreas. Though peripheral trained 
immunity has been documented, the specific signaling mechanism responsible for the 
recruitment of trained innate cells from the bone marrow to a specific organ to establish 
peripheral trained immunity has not been well defined. We speculate that cluster 3 and 4, 
from the scRNA-seq data, may likely represent such BM-derived cells that are directed to 
the pancreas due to the CCL2 signaling that occurs shortly after WGP arrives there. These 
subsets of cells are only present more than 3 days following WGP treatment and show high 
levels of CCR2, an M1 polarization phenotype and gene upregulations consistent with the 
induction of trained immunity.  
As after WGP treatment we had observed a disappearance of the resident macrophage 
population, likely due to a phenotypic shift, we did wonder whether resident macrophages 
may be involved in the initiation of CCL2 production that recruits CCR2+ cells to the 
pancreas.  To address this we tried to deplete resident pancreatic macrophage populations, 
however this proved to be challenging. The use of both liposomal clodronate and anti-
F4/80 mAb depleted macrophages systemically, such as in the spleen, but was not effective 




determine if the peritoneal macrophages that phagocytose WGP, resident macrophages or 
other cell types in the pancreas are responsible for initiating CCL2 signaling. CCL2 is also 
highly produced by stromal cells, so it may be the case that resident macrophage 
populations do not directly secrete CCL2, but rather impact other cell types within the 
pancreas to produce CCL2.    
We also showed that CCR2+ cells account for a large percent of the proliferating Ki67+ 
cells in the pancreas following WGP training. Taken together these results suggest that the 
increase in trained myeloid cells may be due to several mechanisms including the influx of 
peritoneal macrophages, trafficking of CCR2+ cells to the pancreas from the periphery, and 
through in situ expansion of trained resident macrophages. Notably, the currently reported 
study is the first time that CCR2 has been identified as a requisite to the establishment of 

















THE ANTI-TUMOR ROLE OF -GLUCAN-INDUCED TRIANED IMMUNITY IN 




CHAPTER IV INTRODUCTION 
  
Our investigations up to this point have shown that WGP treatment incites an influx 
of myeloid cells into the pancreas that show a phenotype of trained immunity and M1 
polarization. Not only this, but WGP trafficking to the pancreas was also shown to 
reprogram the M2 resident macrophages of the pancreas into a more inflammatory 
phenotype. Moreover, these studies revealed in both in vitro and in vivo settings that 
pancreatic CD11b+ cells that had been exposed to WGP produced increased anti-
inflammatory cytokines, such as TNF- and IL-6, upon re-exposure to a secondary 
stimulus, LPS. It is known that there are a plethora of stimuli that can serve as the second 
signal in -glucan-induced trained immunity. However, the majority of studies have used 
bacteria or viruses as a secondary stimulus, and thus have been mainly been targeted at 
understanding whether the induction of trained immunity may be useful against pathogenic 
infections. Further, while the two studies regarding trained immunity and cancer  discussed 
in the introduction do investigate whether the induction of trained immunity in mice can 
lead to anti-tumor effects, they do not directly investigate if the trained response can be 
directly elicited by exposure of trained cells to a tumor cell or the soluble factors that tumor 




an effective second signal to cells previously trained by -glucan (Fig 4.1). 
Additionally, given the influx of trained immune cells that we had observed, in this chapter 
we will explore the anti-tumor mechanisms of trained immunity specifically in a model of 




CHAPTER IV RESULTS  
 
 
WGP-trained pancreatic infiltrating myeloid cells elicit potent trained responses to 
factors secreted from pancreatic cancers and exhibit enhanced phagocytosis and 
ROS-mediated cytotoxicity 
As we have shown that using WGP as an initial stimulus results in innate immune cells 
that are trained to respond more robustly to a secondary exposure of LPS, and that these 
cells accumulate in the pancreas following treatment, we wanted to know whether 
secondary stimuli related to pancreatic tumors may also elicit this trained response. To this 
end, we first investigated whether pancreatic cancer cells themselves are capable of 
eliciting the WGP-induced trained response. To probe this question, peritoneal 
macrophages were cultured with PBS or WGP in vitro for 24 hours and then washed, 
followed by a 7-day resting period. On day 7, cells were restimulated with LPS, the 
supernatant from cells cultured from a naïve mouse pancreas, and the supernatant from 
cultured KPC cells, which are a cell line of a pancreatic tumor on a C57BL/6 background 
derived from the LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre (KPC) or Pan02 pancreatic 
cancer cells for 24 hours.  TNF- production in the supernatant was measured by ELISA. 




previously trained macrophages, the supernatant from cultured KPC and Pan02 pancreatic 
cancer cells stimulated more TNF- production in -glucan trained macrophages (Fig 
4.2A). To control for the possibility that the process of phagocytosis itself may cause cells 
to become activated, peritoneal macrophages were cultured with 3m polystyrene 
microparticle beads, the cells were allowed to rest for 7 days, and cells then were 
restimulated with PBS or LPS (Fig 4.2B). Results showed that enhanced production of 
TNF was specific to WGP training.   
This was then tested in an ex vivo setting in which mice were treated with PBS or WGP 
and 7 days later pancreatic myeloid cells were harvested and restimulated with the 
supernatants from cultured KPC (Fig 4.3A) or Pan02 cells (Fig 4.3B). It showed that WGP 
in vivo trained CD11b+ myeloid cells in the pancreas produced significantly more TNF- 
in response to tumor-conditioned media.  
We had shown that tumor cell supernatants function as secondary stimulus to trained 
cells, however there are a multitude of factors within the tumor conditioned media that may 
specifically function as the second stimulus in trained immunity. It is known that pancreatic 
tumor cells express high levels of damage-associated molecular patterns (DAMPs) and 
pro-inflammatory factors, and we hypothesized that some of these specific factors may 
evoke the trained response. KPC cells are known to secrete high levels of both macrophage 
migration inhibitory factor (MIF) and high mobility box protein-1 (HMGB1). MIF is a 
cytokine that is known to be secreted in high concentrations by pancreatic tumors that can 
act directly on myeloid cells [201, 202].  Indeed, MIF was present in the supernatant of 
KPC and Pan02 cells as assessed by ELISA (Fig 4.4A). We thus hypothesized that MIF 




the setting of WGP-induced trained immunity. To investigate this, pancreatic myeloid cells 
from in vivo WGP-trained mice were restimulated with a similar concentration of 
recombinant MIF (rMIF) as present in tumor conditioned media. As shown in Fig 4.4B, 
pancreatic myeloid cells previously trained with WGP showed enhanced TNF- 
production upon rMIF restimulation. Re-stimulating WGP-trained cells with HMGB1 also 
was shown to elicit the trained response (Fig 4.5). Collectively, these data suggest the novel 
concept that pancreatic tumor cells, through soluble factors that they release, can serve as 
the second signal to activate myeloid cells in the pancreas that have been trained by WGP.    
We next examined whether these WGP-trained innate immune cells have enhanced 
intrinsic anti-tumor properties. RNA-Sequencing data indicated that phagocytosis-related 
mechanisms were upregulated in the WGP setting, which we hypothesized could be one 
mechanism of anti-tumor functionality (Fig 4.6). CD45+ pan immune cells and CD11b+ 
myeloid cells from WGP-trained mouse pancreas were harvested and assayed for 
phagocytotic potential using the Invitrogen pHrodoTM Green S. aureus BioParticlesTM 
Phagocytosis Kit. WGP treatment led to a significant increase in the phagocytic potential 
of overall CD45+ immune cells (Fig 4.7A) and in CD11b+ myeloid cells (Fig 4.7B).  In 
addition, in vivo trained myeloid cells showed an increase in the phagocytosis of KPC 
tumor cells (Fig 4.8). We then assessed whether myeloid cells trained by WGP show an 
increased cytotoxicity to KPC cells. RNA-Seq data indicated that DEGs related to reactive 
oxygen species (ROS) biosynthetic processes and positive regulation of ROS metabolic 
processes were significantly enriched in WGP-treated myeloid cells (Fig 4.9A). As a result, 
we hypothesized that the upregulation of ROS production by WGP would result in 




hypothesis, CD11b+ cells from the pancreas were isolated from -glucan trained or 
untrained mice. Acquiring enough CD11b+ cells from an untrained mouse pancreas was 
challenging, as only 1% of total cells are CD45+ in pancreas. As such, our assay was limited 
to a maximum of 1:20 for the tumor cell:CD11b+ cell ratio. CD11b+ cells were plated with 
luciferase expressing KPC cells (KPCLuc+) for 24 hours. The luciferase released into the 
supernatant was quantified using the Luciferase Assay Reagent. WGP-trained myeloid 
cells showed a 3-fold increased cytotoxicity towards KPC tumor cells, and the inhibition 
of ROS production using the ROS inhibitor N-Acetyl Cysteine (NAC) completely 
abrogated the WGP-elicited increase in cytotoxicity (Fig 4.9B). Ultimately, these data 
identifies that pancreatic tumor cells are capable of reactivating WGP-trained infiltrating 
myeloid cells in the pancreas, and that these cells show enhanced phagocytosis and ROS-
mediated cytotoxicity.  
 
WGP-induced trained immunity reduces tumor growth and prolongs survival in 
orthotopic models of pancreatic cancer 
We next investigated whether -glucan-mediated trained innate immune responses in 
the pancreas would result in the establishment of an anti-tumor microenvironment that may 
be sufficient to overcome the characteristically immunosuppressive TME of PDAC. 
Accordingly, mice were given 1 dose of either PBS or WGP on day -7 and on day 0, 1x105 
KPC or KPCLuc+ cells were orthotopically implanted into the tail of the pancreas (Fig 
4.10A). At day 21 mice were euthanized and the tumor weight was measured or (Fig 
4.10B). In the setting of injection of KPCLuc+ cells, mice were injected with luciferase 




of photon counts/second (Fig 4.10C). Both studies showed a remarkable reduction in tumor 
burden as a result of WGP treatment, and survival was also significantly prolonged in mice 
trained with WGP (Fig 4.10D). Immunophenotyping of the tumors showed a persistent 
increase in CD45+ immune cells, CD11b+ myeloid cells and F4/80+ macrophages in the 
WGP-trained setting (Fig 4.11A). CD11b+ myeloid cells (Fig 4.11B) and CD11b+F4/80+ 
macrophages (Fig 4.11C) within the tumor also showed a significant increase in TNF- 
production due to WGP.  Both an increased number of CD11b+ myeloid cells (Fig 4.11D, 
left) and an increase in the percent of CD11b+ cells producing TNF- (Fig 4.11D, right) 
significantly correlated with decreased tumor burden. Neither CD4+ nor CD8+ T-cells 
showed increased IFN-, further supporting that the reduction in tumor burden was driven 
by the WGP-trained myeloid cells (Fig 4.11E). Similar antitumor effects were also 
observed in mice orthotopically implanted with Pan02 tumors (Fig 4.12A). To further 
confirm that innate immune cells are responsible for the observed anti-tumor immune 
responses, orthotopic KPC tumors were implanted into NSG mice. Similar to WT mice, 
NSG mice also showed a significant reduction in tumor size due to WGP training, 
confirming that the anti-tumor effects of WGP were driven by innate immune cells and 
functioned independently of adaptive responses (Fig 4.12B). Kalafati et al had shown that 
innate immune training of granulopoiesis promotes anti-tumor immunity [203]. While we 
had not seen an important contribution of granulocytes to our phenotype of trained 
immunity, we examined whether granulocytes are involved in WGP-dependent reduction 
in pancreatic tumors. We administered anti-Ly6G mAb or isotype control mAb on day -2, 
4, 10 and 16, injected mice with PBS or WGP on day 0 and implanted orthotopic KPC 




with the pancreatic tumor burden were assessed (Fig 4.13B). Our results showed a 
significant reduction in tumor size in the WGP group in the absence of neutrophils.  
Given that a complete inhibition of innate immune cell trafficking into the pancreas 
and training of pancreatic myeloid cells following WGP treatment in CCR2-/- mice, we 
reasoned that CCR2-/- mice would also not show the beneficial anti-tumor immune effects 
of WGP training. In line with this hypothesis, CCR2-/- mice that received WGP did not 
show a reduced tumor burden (Fig 4.14) as compared to WT mice. We also utilized an 
admix model where sorted CD11b+ CCR2- and CCR2+ cells were mixed with KPC tumor 
cells and implanted orthotopically into WT mice. Tumors implanted with CCR2+ cells 
showed a decreased tumor burden (Fig 4.15)  Together, these findings demonstrate that 
CCR2 is requisite for the WGP-driven influx of trained innate immune cells into the 
pancreas and that those are consequential for the anti-tumor effects. CyTOF was also 
performed on these samples to see if there were phenotypic differences. A significant 
increase in the relative frequency of CD8+ T-cells and a decrease in the relative percent of 
CD11b+ myeloid cells were observed in the tumors that had been admixed with CCR2+ 
cells (Fig 4.16).  
 Though CCL2-CCR2 signaling had been identified to be critical in the recruitment of 
trained monocyte-derived macrophages to the pancreas, we also wanted to know whether 
the presence of trained HSCs in the bone marrow alone was sufficient to recruit CCR2+ 
cells to the pancreas to slow the growth of orthotopic pancreatic tumors. A BM chimera 
model was used where B6/SJL (CD45.1) mice were treated with PBS or WGP and 7 days 
later their BM was harvested and transplanted into lethally irradiated (950 cGy) WT 




orthotopic KPC tumors and tumor size was assessed 14 days later (Fig 4.17). Tumor size 
between the two groups was the same. First, this indicates that the mechanism of peripheral 
trained immunity in the pancreas is different than other models of trained immunity which 
appear to be entirely driven by the induction of trained immunity in the bone marrow. 
Second, this shows that the trafficking of WGP to the pancreas, which upregulates CCL2 
signaling, is likely necessary to recruit trained monocytes from the bone marrow directly 
to the pancreas.  
 
Trained innate immunity synergizes with anti PD-L1 mAb therapy to prolong 
survival and can also be used in the treatment setting 
Although the significant reduction in tumor burden was shown due to WGP training, it 
is the case that all mice developed fatal tumors. Through scRNA-Seq analysis, we observed 
a distinct expression of CD274 (PD-L1) on myeloid clusters (Fig 4.18A). RNA-Seq data 
also showed that CD274 was upregulated following WGP training (p = 3.37x10-4). 
Analyses of orthotopic KPC tumors also indicated that while the tumor cells themselves 
did express some PD-L1, macrophages and DCs in the TME expressed the highest levels 
of PD-L1 (Fig 4.18B). This is important as it has been reported that host expression of PD-
L1 determines the efficacy of PD-L1 pathway blockade-mediated tumor regression. This 
leads us to hypothesize that WGP training may act synergistically with anti-PD-L1 mAb 
to further prolong mouse survival [204].   
 To assess whether anti-PD-L1 mAb therapy synergizes with WGP-induced trained 
immunity in the pancreas, mice were given WGP on day -7, implanted with orthotopic 




IgG2b isotype control mAb. As has been shown in several clinical trials, anti-PD-L1 
therapy alone failed to prolong survival even beyond that of the IgG2b isotype control mAb 
treated mice (Fig 4.18C). WGP-trained mice did survive significantly longer than IgG2b 
isotype and anti-PD-L1treated mice. However, combination of WGP and anti-PD-L1 
together prolonged survival most effectively. This shows that there is a clinical benefit to 
combining WGP with anti PD-L1 immuno-checkpoint blockade therapy.  
Thus far, the use of WGP has been described in a setting in which WGP is administered 
before tumor cells are implanted. Considering the reduction in tumor size of this model, 
we also tested a more clinically relevant model in which mice were implanted with 
orthotopic KPC tumors and WGP was used to incite trained immunity thereafter. Two 
doses were given; the first after mice had recovered from surgery and a second one week 
later (Fig 4.19). In the therapeutic setting, the WGP-driven influx of trained myeloid cells 
to the pancreas was also shown to prolong survival. Together, these data suggest that the 
initiation of trained immunity in the pancreas using WGP has relevant clinical applications 
in treating pancreatic cancer that necessitate further translational research and 
investigation. Finally, we wanted to investigate whether WGP combined with anti-PD-L1 
may prolong survival in the therapeutic setting so mice were treated with WGP on day 4 
and 11 following tumor implantation, and were then given three doses of anti-PD-L1. 
Similar to previous results, mice treated with monotherapy of anti PD-L1 did not have a 
survival benefit beyond untreated mice, WGP treated mice did show prolonged survival as 
compared to PBS and anti-PD-L1 treated mice, and mice treated with WGP and PD-L1 













Figure 4.1: Schematic of the anti-tumor effects of WGP-induced trained immunity in 
the setting of pancreatic cancer  
Injection of WGP and trafficking of WGP to the pancreas causes the influx of trained innate 
immune cells to the pancreas. These cells have gone epigenetic, metabolic, mitochondrial 
and transcriptional reprograming and when they then come into contact with pancreatic 


























Figure 4.2: Tumor conditioned media elicits a trained response in vitro  
(A) Peritoneal macrophages were acquired from WT mice and were stimulated in vitro 
with PBS or WGP for 24 hours. Cells were allowed a resting period of 7 days followed by 
restimulation with PBS, LPS, the supernatant from cultured and untreated pancreatic cells, 
or the supernatant from cultured KPC or Pan02 pancreatic cancer cells for 24 hours. The 
amount of TNF released over the 24 hours was quantified using an ELISA. (B) Peritoneal 
macrophages were acquired from WT mice and were stimulated in vitro with PBS, WGP, 
or 3 μm polystyrene beads for 24 hours. Cells were allowed a resting period of 7 days 
followed by a 24 hour restimulation with PBS or LPS. The amount of TNF released over 
the 24 hours was quantified using an ELISA. Data are represented as mean ± SEM. ns= 



























































































































































Figure 4.3: Tumor conditioned media elicits a trained response ex vivo  
 
(A+B) WT mice were treated with PBS or WGP and 7 days later pancreatic cells were 
processed and restimulated with the supernatant from cultured (A) KPC or (B) Pan02 
pancreatic cancer cells. Data are represented as mean ± SEM. ns= non-significant; *p <.05, 
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Figure 4.4: MIF secreted by tumor cells elicits the trained response  
(A) The amount of rMIF in the supernatant from cultured untreated WT pancreatic cells, 
KPC cells and Pan02 cells was measured using an ELISA. (B) WT mice were treated with 
PBS or WGP and 7 days later pancreatic cells were processed and restimulated with 10 












Figure 4.5: Recombinant HMGB1 elicits the trained response  
 
WT mice were treated with PBS or WGP and 7 days later pancreatic cells were processed 
and restimulated with 10 ng/mL of mouse HMGB1. Data are represented as mean ± SEM. 
ns= non-significant; **p <.01 























































































































Figure 4.6: WGP treatment positively regulates genes realtedto phagocytic cellular 
processes 
Enrichment plots (GSEA) and heat map of genes related to the positive regulation of 

















































Figure 4.7: WGP training increases phagocytosis of a pHrodo Green Staph Aureus 
particle 
(A) The percent of CD45+ pancreatic cells that phagocytosed a pHrodo Green Staph Aureus 
particle in PBS and 7-day WGP mice along with the MFI of the pHrodo Green Staph 
Aureus particle. (B) The percent of CD11b+ myeloid pancreatic cells that phagocytosed a 
pHrodo Green Staph Aureus particle in PBS and 7-day WGP mice. Cells were first gated 
on the CD45+ population. The MFI of the pHrodo Green Staph Aureus particle is shown. 



























































































































Figure 4.8: WGP training increases phagocytosis of KPC tumor cells  
The percent of CD11b+ myeloid pancreatic cells that phagocytosed KPCGFP+ tumor cells in 
PBS and 7-day WGP mice. Cells were first gated on the CD45+ population. The MFI of 























































































Figure 4.9: WGP treatment enhances cytotoxicity of myeloid cells against tumor cells 
(A)  Enrichment plots (GSEA) and heat map of genes related to the reactive oxygen species 
biosynthetic processes and the positive regulation of reactive oxygen species metabolic 
processes in CD11b+ cells from 7-day WGP-trained as compared to PBS mice. (B) 
Summarized results from a cytotoxicity assay where CD11b+ cells from PBS and 7-day 
WGP-trained mice were sorted and incubated at a ratio of 1:20 KPCLuc+: CD11b+ cells for 
24 hours. NAC was used to block ROS expression and the tumor cytotoxicity was assessed 
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Figure 4.10: WGP treatment decreases tumor size in an orthotopic model of 
pancreatic cancer  
(A) Experimental schema. (B) C57BL/6 mice received a single IP injection of WGP or 
PBS and 7 days mice were implanted orthotopically with KPC pancreatic cancer cells. 
Representative pictures of tumors and quantitative analysis of tumor weight are shown. 
Tumor weight was measured at day 21 (PBS n=5, WGP n=5). (C) C57BL/6 mice received 
a single i.p. injection of WGP or PBS and 7 days later were implanted orthotopically with 
KPC+Luc pancreatic cancer cells. On day 21post tumor implantation, mice were given I.P.  
luciferin bioluminescent substrate and were placed in a photon imager to measure tumor 









































































































Figure 4.11: Immune phenotyping of PBS vs WGP treated pancreatic KPC tumors 
(A) Phenotyping of the tumors showing the percent of viable cells that are CD45+, the 
percent of the CD45+ population that are CD11b+, and the percent of CD11b+ cells that are 
F4/80+. (B) TNF production in CD11b+ cells from PBS and 7-day WGP-trained that were 
restimulated with LPS. Percent of TNF+ cells and the MFI of TNF are shown. (C) 
Summarized data of TNF production in CD11b+F4/80+ cells from PBS and 7-day WGP-
trained that were restimulated with LPS. Percent of TNF+ cells and the MFI of TNF are 























































































































































CD11b% vs Tumor Weight









































CD11b+ (left) and the percent of CD45+CD11b+TNF+ cells (right). (E) Summarized data 
of the percent of CD4+ and CD8+ T-Cells expressing IFN. Data are represented as mean 
± SEM. Pearson correlation coefficients were used to measure the strength of the linear 



















Figure 4.12: Additional tumor models to test the anti-tumor effects of WGP  
(A) C57BL/6 mice received a single i.p. injection of WGP or PBS and 7 days mice were 
implanted orthotopically with Pan02 pancreatic cancer cells. Representative pictures of 
tumors and quantitative analysis of tumor weight are shown. Tumor weight was recorded 
at day 21 (PBS n=5, WGP n=5). (B) NSG mice were treated with either PBS or WGP and 
7 days later orthotopic KPC pancreatic tumors were implanted. 21 days following tumor 
implantation, mice were euthanized and tumor weight was recorded. Data are represented 





































































Figure 4.13: Neutrophils are not involved in the anti-tumor effects of WGP 
(A+B) To deplete neutrophils, mice were treated with anti-Ly6G mAb or anti-rat IgG2a 
isoype control on day -2. On day 0 mice were treated with PBS or WGP and on day 7 mice 
were implanted with orthotopic KPC pancreatic tumors. Additional doses of the anti-Ly6G 
mAb or anti-rat IgG2a isoype control were given on days 4, 10 and 16 to maintain the 
Ly6G depletion. On day 21, mice were euthanized and (A) the depletion efficiency was 
assessed and (B) tumor weight was measured. Data are represented as mean ± SEM. **p 
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Figure 4.14: WGP does not reduce tumor burden in CCR2-/- mice 
 
C57BL/6 were treated with PBS or WGP and CCR2-/- mice were treated with WGP and 7 
days later were implanted with orthotopic KPC pancreatic tumor cells. Tumor weight and 
size was monitored for 3 weeks after implantation and tumor weight at day 21 is reported. 
(WT PBS n=5, WT WGP n=5, CCR2-/- WGP n=5). Data are represented as mean ± SEM. 






Figure 4.15: CCR2+ and CCR2- admix tumor model  
WT mice were treated with WGP and 7 days later the CD11b+ and CD11b- populations 
were sorted, mixed with KPC tumor cells and implanted orthotopically into WT mice. 21 



















































































































Figure 4.16: CyTOF of admix CCR2+ and CCR2- admix KPC tumors 
CyTOF analysis was performed on CCR2+ and CCR2- admixed tumors. The percent of 
CD8+ and CD11b+ cells in the tumors was assessed and is shown in representative images.  









Figure 4.17: Bone marrow chimera model to assess the role of central trained 









































































































































 B6/SJL (CD45.1) mice were treated with PBS or WGP and 7 days later 2x106 BM cells 
were transplanted into lethally irradiated WT (CD45.2) mice. 6 weeks after transplantation, 
recipient mice were implanted with orthotopic KPC tumors and tumor size was evaluated 





















Figure 4.18: WGP synergizes with anti-PD-L1 immunotherapy to prolong survival   
(A) scRNA-Seq data showing a UMAP of the myeloid clusters expressing CD274. (B) 
Experimental schema of WGP and anti PD-L1 therapy. Mice (n=5) were treated with PBS 
or WGP and 7 days later were implanted with orthotopic KPC pancreatic tumors. On days 
3,7 and 11 post-tumor implantation, mice were given anti-PD-L1 mAb or anti-rat IgG2b 
mAb isotype control. Survival of mice was monitored.**p <.01, ****P<.0001 
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Figure 4.19: WGP used in the adjuvant setting  
Experimental schema of WGP used in the therapeutic setting.  Mice were implanted with 
orthotopic KPC pancreatic tumors and were given WGP once mice had recovered from the 












Figure 4.20: WGP can be combined with anti-PD-L1 mAb therapy in the adjuvant 
setting 
Mice were treated with PBS or WGP on day 4 and 11, and were then given 100 g of anti-





































































CHAPTER IV DISCUSSION 
 
As we show that peripheral trained immunity has been established in the pancreas, an 
important question is whether this nonspecific innate immunological memory could be 
reactivated by tumor cells or their secreted factors. Re-exposure of in vivo WGP-trained 
pancreatic myeloid cells to tumor conditioned media vigorously elicits a potent trained 
response. While Kalafati et al recently showed a role for granulocytes in trained immunity 
driven anti-tumor mechanisms [203], the currently reported study is the first instance 
suggesting that myeloid cells in a specific organ can be trained to react directly to tumor 
cells of that same organ. Further, while we highlight that tumor-conditioned media can re-
activate trained myeloid cells, we also identify specific factors in the tumor-conditioned 
media that are involved in this activation. MIF, which is known to be primarily secreted by 
tumor cells and whose primary targets are myeloid cells [205, 206], was found to be 
actively secreted by both Pan02 and KPC tumor cells. Using this average concentration of 
rMIF to re-stimulate WGP-trained cells showed that MIF can activate trained myeloid 
cells. We also show that HMGB1 can elicit the trained response. Others have reported that 
DAMPs can be involved in trained immunity, however have primarily shown that they can 
act as the initial training stimulus [207]. It has not been previously shown that DAMPs 
secreted by tumor cells can re-stimulate trained cells. This understanding has implications 
for which cancer cell types may be most capable of re-stimulating trained cells based on 




factors that may also function to re-activate trained myeloid cells and may activate them to 
different extents, and further investigation into these specific factors may shed more light 
on the anti-tumor capabilities and mechanisms of trained immunity. Ultimately, we also 
identify the novel concept that specific factors released by tumors and tumor cells 
themselves can act as the second signal in the incitement of trained immunity.  
While often the anti-tumor mechanisms of myeloid cells are thought to be indirect and 
orchestrated through the activation of adaptive immune cells, here we show that WGP 
training upregulates the direct anti-tumor functionalities of myeloid cells in the pancreas.  
Due to WGP training we observed enhanced phagocytosis of tumor cells and ROS 
mediated cytotoxicity to tumor cells. Inhibiting ROS production abrogates the cytotoxicity 
of WGP-trained myeloid cells. Supporting results of the cytotoxicity assay, CyTOF data, 
RNA-Seq data and scRNA-Seq data all identify substantial enhancements in the expression 
of ROS-related molecules/genes in these trained cells, though other groups have submitted 
that training by -glucan is not associated with increased production of ROS by 
macrophages/monocytes [125, 208]. This finding suggests that the phenotype of trained 
immunity induced by particulate -glucan in the pancreas may be unique. Supporting our 
results, several studies have characterized the mechanism of BCG-trained macrophages 
cytotoxicity against bladder cancer cells. Such studies indicate that the cytotoxic effects 
are due to both enhanced cytokine production and the production of ROS [209-211].   It is 
also worth noting that while our findings show that ROS production is an important 
contributor to the anti-tumor phenotype, in the complex tumor setting there are likely 
additional pathways that play a significant role in the tumor surveillance and control 




We then translate our findings regarding the anti-tumor potential of the trained innate 
myeloid cells that enter the pancreas to orthotopic models of pancreatic cancer, where we 
observe a dramatic decrease in the tumor size and an increase in the survival of mice given 
only one I.P administration of WGP.  We also observe a reduction of tumor size in mice 
with both KPC and Pan02 tumors, revealing that these myeloid-driven anti-neoplastic 
effects are broadly applicable to pancreatic tumors. Importantly, through the depletion of 
neutrophils, along with the use of NSG mice and CCR2-/- mice, we demonstrate that the 
cells responsible for tumor control are innate myeloid-derived cells that traffic to the 
pancreas through CCL2-CCR2 signaling. 
BM chimeric models support that the presence of trained immunity within HSCs in the 
bone marrow is not enough on its own to slow the growth of pancreatic tumors, which is 
in contrast to other proposed models of peripheral trained immunity. Instead, the early 
trafficking of WGP to the pancreas and the resulting production of CCL2 by cells in the 
pancreas recruit trained CCR2+ myeloid cells from the circulation and periphery,  which 
contribute to the antitumor effects. It is important to point out that given how quickly 
trained immune cells arrive in the pancreas, it is unlikely that these cells are directly from 
the bone marrow, though further investigations are needed to ascertain the source of 
incoming trained myeloid cells.  We also show that several new populations of 
macrophages and monocytes exist in the pancreas following WGP training, all of which 
display features of trained immunity. It is thus likely the case that in this model there is not 
a single cell type that is responsible for the slowed tumor growth, but rather the result of a 
juxtaposition of an increase in pro-inflammatory trained cells and a decrease in the number 




It has been noted by several studies that the CCR2+ present within a tumor have pro-
tumorigenic roles [212, 213]. In pancreatic cancer, CCL2 production results in the 
mobilization of CCR2+ inflammatory monocytes from the bone marrow to the tumor, 
where they become TAMs [214]. For this reason CCR2 inhibitors used in combination 
with chemotherapy for PDAC have been tested, and ultimately demonstrated a more 
favorable response than chemotherapy used alone [215].  In contrast to these studies,  here 
we demonstrate that CCR2+ cells recruited to the tumor have anti-tumor potential due to 
the fact that they have been trained by WGP. Unlike typical CCR2+ cells recruited to the 
TME, in this model CCR2+ cells recruited to the tumor site have undergone transcriptional 
and metabolic reprogramming that allows them to exert anti-tumor properties within the 
TME. A major downfall of the use of therapeutic use of CCR2 inhibitors is that the 
depletion of TAMs often results in a compensatory influx of tumor associated neutrophils 
(TANs) to the TME which themselves have many pro-tumorigenic roles. Therefore instead 
of using CCR2 inhibitors in the setting of PDAC, it may be more reasonable to consider 
therapies that reprogram CCR2+ cells that will traffic to the  tumor anyways to have anti-
tumor functionalities [216].  
We note high expression of MHC II on trained monocyte/macrophages in the pancreas, 
which likely play a role in tumor antigen processing and communication with T-cells to 
elicit adaptive immune responses against the tumor. While based on NSG tumor studies, 
these antitumor mechanisms do not depend on adaptive immune responses, it is 
conceivable that activated myeloid cells could exert a positive influence on adaptive 
immune cells to aid in the generation and activation of tumor-specific T-cells and in anti-




traffic to the pancreas which bears a tumor already, the arrival of activated myeloid cells 
expressing high levels of MHCII could play an important role in taking up and presenting 
antigen to T-cells. This could result in an enhanced generation of tumor-specific T-cells 
that could exert important anti-tumor effects. Accordingly, models where WGP is 
administered before the tumor is implanted versus after the tumor is implanted may show 
different types of T-cell responses. While this project focuses primarily on the role of 
trained innate myeloid cells and their direct anti-tumor effects, more investigations on the 
consequences of trained innate immunity on anti-tumor T-cell responses is warranted. It 
may also be important to determine if alterations to the T-cell compartment due to WGP 
treatment are responsible for the success of combination therapy of WGP and anti-PD-L1 
therapy or if these effects are solely due to changes to the myeloid cells.  
Another focus of future investigations is the  optimization of WGP treatment in terms 
of dosing and the number of treatments could further extend survival.  While we did 
observe a decrease in tumor size and longer survival due to WGP training, all mice did 
eventually succumb to the tumor, even in combination with anti-PD-L1 therapy.  
Immunosuppressive myeloid cells play a critical role in the creation of the hostile TME 
in PDAC through the inhibition of T-cell effector function and the promotion of cancer 
stemness, angiogenesis, stroma deposition, and metastasis formation [217-219].  While it 
is the case that within the TME tumor secreted factors often reprogram myeloid cells to 
propagate tumor growth, these cells also harbor the potential for robust anti-tumor 
responses [220-222]. A conceivable reason why immunotherapy alone has yet to show 
success in the treatment of PDAC is that these therapies have a primary objective of 




suppressive myeloid cells that promote them. Accordingly, two therapeutic strategies that 
could benefit PDAC patients but that have not yet been successfully implemented in a 
clinical setting are therapeutics that 1) promote the reprogramming of immunosuppressive 
myeloid cells in the PDAC TME, and 2) actively recruitment anti-tumor myeloid cells to 
the tumor that can penetrate the desmoplastic stroma.  Here, we demonstrate a novel 
capability to engage both of these anti-tumor mechanisms in the setting of PDAC through 
the induction of trained innate immunity in the pancreas by particulate  -glucan. 
Importantly, we also show that the novel ability to initiate trained immunity in the pancreas 
potentiates the therapeutic effects of immunotherapy such as anti-PD-L1 immuno-
checkpoint blockade therapy. Lending further clinical applicability to these findings, we 
also exhibit that the induction of TI in the adjuvant setting can decrease tumor size and 
prolong survival. These findings emphasize the potential of using -glucan to  
therapeutically target myeloid cells within the TME and highlight that the induction of 
peripheral trained immunity in the pancreas may have a consequential role in 
reprogramming the suppressive TME of PDAC and in extending the life of patients 









SUMMARY AND FUTURE DIRECTIONS 
 
 
Figure S1: Graphical Abstract  
1) Mice are injected with IP WGP which traffics to the pancreas both in peritoneal 
macrophages and as naked WGP. 2) M2 resident macrophages in the pancreas are 
repolarized to an M1 phenotype after WGP trafficking and WGP also impacts peripheral 
myeloid cells. All cells that come into contact with WGP become trained. The arrival of 
WGP to the pancreas initiates the production of CCL2 and this signaling recruits CCR2+ 
trained myeloid cells from the periphery to the pancreas. 3) When trained cells in the 
pancreas are reactivated by tumor cells and their supernatants, they will produce cytokines 
and ROS in addition to initiating phagocytosis of tumor cells. Together these mechanisms  




The data presented in this dissertation reveal a novel trafficking mechanism of -
glucan to the pancreas that initiates a CCR2-dependent induction of peripheral trained 
immunity and reprogramming of M2-like resident macrophages to M1-like. We show that 
trained cells present in the pancreas following WGP treatment have significant anti-tumor 
functionality, and that tumor cells and the soluble factors that they secrete can function as 
a secondary stimulus to reactivate previously trained cells. Through models of orthotopic 
pancreatic cancer we demonstrate that the induction of peripheral trained immunity in the 
pancreas leads to an overall reduced tumor burden and longer survival (Fig S1).  
We also illustrate that while immunotherapy alone fails to effectively reduce 
pancreatic tumor burden, treatment with WGP synergizes with anti-PD-L1 mAb therapy 
to further prolong survival. Finally, we show that WGP effectively reduces tumor burden 
in the treatment setting. These findings have significant clinical relevance as innovative  
strategies to effectively  target and treat pancreatic cancer are desperately needed.  
One potential challenge in the translation of these results to the clinical setting 
comes from the intraperitoneal route of administration of the WGP. While more invasive 
than intravenous or oral administration, IP injection is a commonly utilized clinical practice 
in the treatment of a variety of malignancies including ovarian and mesenteric cancer [223-
225]. Importantly, the current standard of care for patients with pancreatic cancer often 
necessitates a surgeon to gain access to the peritoneal cavity providing an opportunity to 
deliver IP WGP without requiring additional surgical intervention. For example, a patient 
diagnosed with stage I or II PDAC will usually receive a diagnostic laparoscopy one week 
prior to final surgical resection followed by adjuvant chemotherapy. In this case, WGP 




resection. In the case of a patient with locally advanced stage III disease, they will often 
receive neoadjuvant FOLFIRINOX treatment followed by a diagnostic laparoscopy one 
week prior to treatment with irreversible electroporation (IRE) [226, 227]. Both the 
diagnostic laparoscopy and the IRE procedure would provide an opportunity to administer 
IP WGP.  At this time we are in the process of generating additional safety data that would 
support the creation of a clinical trial. Additionally, we are investigating whether the IP 
administration of WGP to pigs also results in an influx of trained innate immune cells to 
the pancreas. Should these studies have positive results, future studies will aim to 
investigate whether the administration of IP WGP may help in prolonging the survival of 
human patients diagnosed with pancreatic cancer. These studies would involve 
investigation into the ideal dose and timing of WGP administration, and would also detail 
if WGP treatment synergizes with therapies such as IRE or immune-checkpoint blockade 
therapy.  
As checkpoint inhibitor monotherapy has failed to improve patient outcomes in the 
setting of PDAC, none of these therapies are currently approved for use in PDAC patients 
[6]. The highly immunosuppressive microenvironment of PDAC poses a significant 
challenge to the efficacy of immunotherapies, as does the dense desmoplastic stroma and 
infiltration of immunosuppressive myeloid cells. Our studies highlight that strategies to 
reprogram the myeloid compartment within PDAC may prove to be effective in unleashing 
the potential of immunotherapy. Thus, further investigations into the mechanisms that 
allow WGP to synergize with anti PD-L1 therapy are needed as they may elucidate 
important underlying mechanisms regarding resistance to immunotherapy that can be 




As discussed earlier, the specific tropism of WGP to the pancreas is also a novel 
finding and carries with it the potential to load WGP with other therapeutics such as 
chemotherapy or siRNA and have them directly delivered to the pancreas. More studies 
are certainly warranted to investigate why WGP shows specific tropism to the pancreas 
and whether this phenomenon is based on an anatomical or chemical mechanism. 
Additionally, while the induction of trained immunity in the pancreas was shown to directly 
have anti-tumor effects, the delivery of cancer therapeutics directly to the pancreas in the 
setting of PDAC provides a major challenge to its treatment.  Further, systemic therapies 
such as chemotherapy often result in high degrees of toxicity that contribute to patient 
morbidity and mortality, and often do not effectively target the intended organ because of 
altered vasculature due to angiogenesis. Hence future studies may focus entirely on how 
this tropism of WGP to the pancreas can be manipulated to deliver effective doses of anti-
tumor therapeutics. For example, WGP particles loaded with siRNA against PD-L1 could 
traffic to the pancreas where they not only could induce peripheral trained immunity due 
to the presence of WGP, but may also be taken up by resident macrophages and DCs in the 
TME, which would result in decreased PD-L1 expression and enhanced T-cell activation 











Figure S2: Schematic of the use of WGP particles loaded with anti-tumor agents to 
target the pancreas  
 
Finally, the induction of peripheral trained immunity in a visceral organ has not 
been previously reported. Though peripheral trained immunity has been identified to exist, 
how it is initiated in a specific organ has not been investigated before. This work identifies 
that WGP arrival to the pancreas stimulates the production of CCL2 which likely plays a 
major role in recruiting CCR2+ trained myeloid cells to the pancreas that can be 
restimulated by tumor cells. We also assume that immunosuppressive resident 
macrophages in the pancreas undergo repolarization due to the arrival of WGP to the 
pancreas. It is possible that injection of WGP to a specific organ may also result in a similar 
signaling mechanism that would result in anti-tumor effects, and so future studies are 
needed to investigate whether the mechanism outlined in this paper is specific to the 







Six to eight week-old female wild-type (WT) C57BL/6J mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME, USA) or bred in the University of Louisville specific 
pathogen-free (SPF) animal facility. C57BL/6 Dectin-1 knockout  (Dectin-1 -/-) mice were 
described previously [228].  CCR2 global knock-out mice were purchased from Jackson 
Laboratory. Albino C57BL/6 mice were kindly provided by Dr. Jonathan Warawa at the 
University of Louisville. NOD/SCID/IL2rNull (NSG) mice and B6/SJL-CD45.1 were 
purchased from the Jackson Laboratory. All mice were at least 6 weeks of age upon use, 
and all experiments involving animals were performed in compliance with all relevant laws 
and institutional guidelines provided by the Rodent Rearing Facility (RRF) and approved 
by the Institutional Animal Care and Use Committee (IACUC) of the University of 
Louisville. 
 
Preparation of -glucan:  
Highly purified particulate -glucan in the form of particulate Whole -glucan Particles 
(WGP) isolated from Saccharomyces cerevisiae was provided by Biothera. Before use, 
WGP was gently sonicated for 15 seconds, 2 times using a Qsonica Q55-110 Q55 Sonicator 
(Cole-Parmer) to ensure aggregates were broken up.  
 




DTAF (Sigma Aldrich) at 2mg/mL was mixed with a suspension of 20mg/mL WGP in 
borate buffer (pH 10.8). This incubated at room temperature for 8 hours with continuous 
mixing.  Following incubation, the WGP was centrifuged and washed with cold sterile 
endotoxin-free DPBS (Sigma Aldrich) 5 times or until the supernatant no longer contained 
visible DTAF. The concentration was adjusted to 10mg/mL in the endotoxin-free DPBS 
for storage. 1mg of the DTAF WGP was injected IP into C57BL/6  and Dectin-1 -/- mice 
and organs were harvested 3 days later.  
Preparation of the 89Zr-WGP:   
WGP (100 mg) was mixed with Deferoxamine-SCN (2.7 mg, in 0.8 ml DMSO) and 
suspended in 10 ml sodium carbonate buffer (0.1 M, pH 9.4) overnight at room temperature 
in the dark with gentle shaking. The Deferoxamine-labeled WGP was then washed with DI 
water (10X 40 mL), and 30 mg of Deferoxamine-labeled WGP was mixed with 3 mCi 
of 89Zr oxalate in 2 ml Tris•HCl buffer (0.5 M, pH 7.5), and then incubated at 37 oC for 60 
min with shaking. The 89Zr-WGP was then centrifuged and washed with 3 ml of sterile 
PBS. The radioactivity of 89Zr-WGP was measured by a dose calibrator and used for in 
vitro and in vivo studies.  
 
Biodistribution and PET/CT Scan using 89Zr-WGP 
Positron Emission tomography (PET)/computed tomography (CT) imaging was conducted 
in C57BL/6  and Dectin-1 -/- mice 48 hours after IP injection of 1mg of pure  89Zr-WGP 
or injection of 1x106 peritoneal macrophages that had been co-cultured with 25g/ml of  
89Zr-WGP for 2 hours and then gently washed to remove excess 89Zr-WGP. The mice 




scan. Siemens IAW soft- ware was used for the acquisition and reconstruction of the PET 
signal, and Siemens IRW software was used for merging and analyzing the imaging data. 
At the end of the imaging study, mice were euthanized, and organs of interest were 
harvested. For biodistribution, 50 uL of peripheral blood was collected using a retrobulbar 
bleeding technique. The brain, heart, lungs, liver, spleen, kidneys, pancreas, large intestine, 
small intestine, stomach, femur, a piece of skin from the flank of the mice and the rectus 
femoris muscle were harvested, weighed, and placed in a 2470 Wizard automatic gamma 
counter (PerkinElmer) in order to measure the radioactivity of each tissue. The CPM values 
were calculated using Prism software (GraphPad Software, La Jolla, CA).  
 
Pancreatic processing  
Following euthanization, mouse pancreas were harvested and gently cut into smaller pieces 
using sterile scissors. They were suspended in a 15mL tube in complete media (RPMI) 
with 1X digestion buffer comprised of 300U/ml collagenase I, 60 U/ml 
Hyaluronidase,  and 80 U/ml DNase (Sigma). These were placed in a rotating incubator at 
37°C with 5% CO2 for 15-20 minutes. The digestion buffer was then quenched with ice 
cold complete RPMI 1640 and washed. Cells were passed through a sterile nylon 40 µm 
basket filter and small undigested pieces of tissue were smashed using a sterile syringe 
stopper in order to generate a single-cell suspension. If an appreciable number of red blood 
cells (RBCs) were seen to exist in the sample, RBC lysis was performed by adding 2mL of 
sterile 10x ACK (Thermo Fisher Scientific).  
 




Mice were given a single 1 mg intraperitoneal dose of gently sonicated WGP, 3 μm 
polystyrene beads (Sigma Aldrich), or  3 μm fluorescent microspheres (Polysciences) (all 
1mg in 200 l of sterile PBS) or 200 l of sterile PBS on day 0.  For typical trained 
immunity studies, 7 days following the initial IP dose, mice were euthanized using CO2 
and the pancreas along with other tissues of interest were removed and processed.  For dose 
titration studies, .5mg, 1mg and 2mg of WGP were delivered IP in 200uL of sterile PBS. 
For time titration studies, mice were injected with 1mg of WGP and the pancreas was 
harvested after 24 hours, 48 hours, 3, 7, 10, 16 and 30 days later.  
 
Ex vivo re-stimulation 
In order to assess the trained phenotype of mononuclear cells in mice treated with WGP or 
PBS ex vivo, after processing the pancreas, pancreatic cell suspensions were plated in 24 
well plates and stimulated with LPS (10ng/ml), the supernatant from cultured KPC and 
Pan02 cells (40%), and recombinant MIF  (rMIF)(10ng/ml).  rMIF was a generous gift 
from Dr. Robert Mitchell at the University of Louisville and was prokaryotically expressed, 
purified, and re-folded a described previously[229].   Cells were cultured in DMEM, and 
incubated at 37C with 5% CO2 for 5-6 hours in the presence of 1X brefeldin A 
(Biolegend). The cells were then harvested using a cell scrapper, washed, pelleted and then 
stained for intracellular cytokine expression.   
 
In vitro training and re-stimulation assay 
Peritoneal macrophages or sorted CD11b+ cells from a mouse pancreas were plated in a 




plates, after which the floating cells were gently aspirated. Attached cells were gently 
washed with sterile PBS and then resuspended in 1mL of DMEM constituted of 10% FBS 
1% penicillin/streptomcymin. For the initial training of cells, 25g/ml of particulate WGP, 
25g/ml of 3m polystyrene microparticle beads (Sigma-Aldrich) or 100 uL of PBS were 
added to the appropriate well and incubated for 24 hours. After 24 hours, wells were gently 
washed to remove the initial stimulus and fresh DMEM was added and cells were incubated 
with 5% CO2 at 37C for 7 days. After 7 days, the media was aspirated, replaced with fresh 
media, and cells were re-stimulated with LPS (100ng/mL), the supernatant of KPC or 
Pan02 cells (40%), or PBS as a control. 24 hours after stimulation, the supernatants were 
harvested and used in an ELISA for TNF- and IL-6.  
 
Tumor conditioned media  
1x106 KPC or Pan02 cells were cultured in a six well plate in 4mL of complete DMEM 
and at 37C and 5% CO2.  After 3 days the supernatants were harvested and stored at -80C 
in aliquots for use as tumor-conditioned medium. As a control, the pancreas of a C57BL/6 
mouse was processed into a single cell suspension and 1x106 of these cells were cultured 
in a six well plate in 4mL of complete DMEM and at 37C and 5% CO2, and supernatants 
were also collected after 3 days.  
 
Acquisition of peritoneal macrophages 
Mice were euthanized and 5mL of sterile RPMI was injected into the peritoneum using a 
25-gague syringe. The abdomen was massaged to liberate the peritoneal macrophages. A 




peritoneal cavity was then washed several times with cold RPMI and cells were pelleted at 
1600 RPM.  
 
Confocal Microscopy  
Mice were injected IP with 1mg of DTAF-WGP and 4 hours later mice were euthanized 
and peritoneal macrophages were harvested. Cells were suspended in 200 uL of sterile PBS 
and were spun onto a microscope slide using a Shandon CytoSpin3 (Thermo Fisher). Slides 
were then air dried for 10 min prior to staining. Cells were fixed with 4% formalin for 30 
minutes, washed with PBS, washed again with a .3% triton solution, and then incubated 
with blocking solution (20% FBS, .3% TritonX) for 1 hours. Cells were then washed and 
incubated with F4/80 primary antibody overnight. Wells were washed and cells were 
incubated with DAPI for 10 minutes. Slides were washed, a cover slip was applied to all 




Single-cell suspensions in PBS with 1% FBS were blocked with murine Fc Block (anti-
CD16/CD32) at 4C for 15 minutes. Fluorochrome labeled antibodies for viability 
(APC/Cy7) and to surface markers CD45, CD11b, F4/80, Ly6G, Ly6C, MHCII, CD3,CD4, 
CD8, NK1.1, Ki67 (Biolegend) and CCR2 (R&D Systems) were used. After 30 minutes of 
incubating in the dark at 4C, cells were washed with cold PBS, and filtered through a 40 
µm mesh filter. The samples were acquired using a FACSCanto II cytometer (BD 





Intracellular staining for expression of cytokines 
Following stimulation, cells  were stained for the desired surface markers as described 
above. The cells were then washed with cold PBS, and 500l of fixation buffer (Biolegend) 
was added to the tubes, briefly vortexed and incubated in the dark at room temperature for 
20 minutes. 1ml of Permeabilization buffer (Biolegend) was then added and samples were 
centrifuged at 1600rpm for 5 minutes at 4C followed by one more wash using 1ml of 
permeabilization buffer. Cells were resuspended in 200 l of permeabilization buffer and 
cells were stained with antibodies against TNF-, Ki67, Granzyme-B, IL-12, IL-6 and 
IFN or the respective isotype control overnight at 4C. Cells were then washed, filtered 
and data was acquired using a flow cytometer.  
 
FACS isolation of CD11b+ macrophages for in vitro training  
The pancreas was processed into a single cell suspension as described above. Cells were 
washed with 1 mL of PBS, incubated with Fc block for 10 minutes at 4C followed by 
staining with viability dye (APC-Cy7), CD45 (PerCPcy5) and CD11b+ (APC) for 30 
minutes at 4C. Cells were washed with PBS and re-suspended in cold MACS Running 
Buffer (Miltenyi Biotech). Viability-CD45+CD11b+ cells were sorted using a FACS Aria 
III (Bd Biosciences). Cells were collected in a 50% FBS,40% PBS, 10% HEPES (Corning).  
After sorting the cells were washed with PBS and then plated for in-vitro training, as 






Supernatants from in vitro trained cells along with standards were analyzed using murine 
TNF- and IL-6 ELISA kits (BioLegend).  The assay was performed per the 
manufacturer’s instructions and all conditions were performed in triplicates.  An ELISA 
kit for r-MIF (R and D systems) was also used according to the manufacturer’s instructions 
in order to quantify r-MIF in Pan02 and KPC tumor conditioned media and the supernatant 
from cultured untreated pancreatic cells.    
 
qRT-PCR 
After CD11b+ cells had been isolated from the mouse pancreas in WGP treated and 
untreated mice, cells were saved in TRIzol. RNAs were isolated and reverse transcribed 
using the TaqMan Reverse Transcription Reagents (qRT-PCR) amplification using the 
BioRad MyiQ single color RT-PCR detection system. Briefly, cDNA was amplified in a 
25uL reaction mixture consisting of SYBR Green PCR super-mix (BioRad), 100 ng of 
complementary DNA template, and selected primers (200 nM) using the recommended 
cycling conditions.  
 
H+E 
7 days following injection with PBS/microparticle beads or WGP, the pancreata were 
harvested and fixed in 4% formalin for 1 week followed by embedding in paraffin 
according to standard procedures. Paraffin embedded tissues were cut into 5mm thick 
sections and strained with hematoxylin and eosin (H & E) for morphological analysis.  
 




Murine serum amylase was measured using the Amylase Activity Assay Kit (Millipore 
Sigma) and was used according to the manufacturer’s instructions. In short, mice were 
injected with WGP and 7 days later, blood was collected from mice using a retro-bulbar 
bleeding technique. These samples were used to assay for serum amylase.  
 
In vivo T-cell depletion 
T-cells were depleted using an anti-CD4 mAb alone, anti-CD8 mAb alone or anti-CD4 and 
anti-CD8 mAbs together. Antibodies were made in-house. In this depletion procedure, 
mice were injected IP with WGP on day 1 and were also injected IP with 200 µg of the 
mAbs at day 1 and day 4 during the treatment period. Mice were euthanized on day 7. (CD-
4 clone GK1.5, CD-8 clone 53-6.72). Depletion efficiency was confirmed on day 7.  
 
In vivo NK cell depletion:  
NK cells were depleted through the intraperitoneal injection of 100 µg of PK136 mAb 
(Produced in the laboratory of Dr. Jun Yan at the University of Louisville) on days -1 and 
5 during the treatment period. WGP was injected at day 0, and on day 7 animals were 
euthanized and the depletion efficiency of NK cells was assessed by staining pancreatic 
tissues for NK1.1.  
 
Ly6G depletion 
Neutrophils were depleted by injecting 300 µg of anti-Ly6G mAb (Bio X Cell) or isotype 
control Rat IgG2a (Bio X Cell) at day -1, 2 and 6 during the course of treatment. 1mg of 




assessed for efficiency of depletion.  In the tumor model mice were injected with 300 µg 
of anti-Ly6G mAb or isotype control Rat IgG2a on day -2, 4, 10 and 16. Mice were given 
WGP at day 0, and were implanted with orthotopic KPC pancreatic tumors on day 7. Mice 
were euthanized on day 21 and pancreatic tissues were stained with Ly6G to assess 
granulocyte depletion efficiency at that time.  
 
CyTOF mass cytometry sample preparation 
Mass cytometry antibodies were either purchased from Fluidigm or were created in house 
by conjugating commercially available purified antibodies to the appropriate metal isotope 
using the MaxPar X8 Polymer or MCP9 Polymer kits (Fluidigm).  Pancreatic samples from 
three PBS and three 7-day WGP mice were processed into a single cell solution and ex-
vivo stimulation was performed as described above. Cells were gently scraped from the 
plates using a sterile cell scraper, washed with PBS and placed into a sterile culture tube.  
2x106 cells per samples were used. Cells were first stained for viability with 5uM cisplatin 
(Fluidigm) in serum free RPMI1640 for 5 minutes at RT. Cells were then washed with 
RPMI1640 containing 10% FBS for 5 minutes at 300xg. Cells were stained with the surface 
antibodies for 30 minutes at RT and washed twice with Maxpar Cell staining buffer 
(Fluidigm). For staining on intracellular cytokines, cells were then fixed with 1 mL of 1X 
Maxpar Fix I buffer for 30minutes at RT and then washed twice with 2 mL of 1X Maxpar 
Perm-S buffer for 5 minutes at 800xg. The cytoplasmic/secreted antibody cocktail was then 
added and incubated with the cells for 30 minutes at RT. Following incubation, cells were 
washed with 1mL of 1X Maxpar Perm-S buffer for 5 minutes at 800xg and gently blotted 




suspended in 1 mL of 1X Maxpar nuclear antigen staining buffer for 30 minutes at RT. 
The nuclear antigen antibody cocktail was then added and incubated for 30 minutes at RT. 
Cells were washed with twice for 5 minutes at 800xg with 2mL of Nuclear Antigen 
Staining Permeability buffer. Finally, cells were fixed with 1.6% formaldehyde for 10 
minutes at RT, then incubated overnight in 125nM of Intercalator-Iridium (Fluidigm) at 
4C.  
 
CyTOF data acquisition  
Once cells were ready for acquisition, samples were washed twice with Cell Staining 
Buffer (Fluidigm) and kept on ice while awaiting acquisition. Directly prior to acquisition, 
cells were suspended in a 1:9 solution of Cell Acquisition Solution: EQ 4 element 
calibration beads (Fluidigm). A Helios CyTOF system was used, and following proper 
startup and tuning procedures, samples were run at a rate of less than or equal to 500 events 
/ second up to 300,000 events.  Using the CyTOF software, .FCS files were normalized 
into .fcs files, and these files were then ready to for data analysis.   
 
CyTOF data analysis  
CyTOF data was analyzed using FlowJo, the CytoBank software package [230], and the 
CyTOF workflow [231] which includes a suite of packages available in R (r-
project.org)[232-235].  For analysis conducted within the CyTOF workflow, FlowJo 
workspace files exported from flow Workspace and CytoML were used [233].  
 




7 days following administration of PBS or WGP IP, pancreata from were harvested, 
processed into a single cell suspension as described previously, stained for viability, CD45 
and CD11b as described previously, and sorted using a FACS Aria III as described 
previously. Samples were prepared in triplicate for each experimental group. Once these 
myeloid cells were isolated, cells were washed 2x with ice cold PBS and then lysed with 
Trizol (Invitrogen). RNAs were extracted using a QIAGEN RNAeasy Kit (QIAGEN). The 
isolated RNA was checked for integrity using the Agilent Bioanalyzer 2100 system 
(Agilent Technologies, Santa Clara, CA) and quantified using a Qubit fluorometric assay 
(Thermo Fisher Scientific, Waltham, MA). Poly-A enriched mRNASeq libraries were 
prepared following the Universal Plus mRNA-Seq kit standard protocol (Tecan Genomics, 
Redwood City, CA) using 10 ng of total RNA. All samples were ligated with Illumina 
adapters and individually barcoded. Absence of adapter dimers and consistent library size 
of approx. 300 bp was confirmed using the Agilent Bioanalyzer 2100. The library 
concentration and sequencing behavior was assessed in relation to a standardized spike-in 
of PhIX using a Nano MiSeq sequencing flow cell from Illumina. 1.8 pM of the pooled 
libraries with 1% PhiX spike-in was loaded on one NextSeq 500/550 75 cycle High Output 
Kit v2 sequencing flow cell and sequenced on the Illumina NextSeq 500 
sequencer targeting 60M 1x75bp reads per sample.  
 
RNA sequencing  
Libraries were prepared using the Universal Plus mRNA-seq kit with with NuQuant® 
library quantification (NuGen). The six samples were spread across four sequencing lines 




Illumina’s BaseSpace [237] (https://basespace.illumina.com/) onto the KBRIN server for 
analysis. Quality control (QC) of the raw sequence data was performed using FastQC 
(version 0.10.1) [238]. The sequences were aligned to the mm10 mouse reference genome 
using STAR (version 2.6) [239], generating alignment files in bam format. Differential 
expression of ENSEMBL protein-coding transcripts was performed using DESeq2 [240, 
241]. Raw counts were obtained from the STAR aligned bam format files using HTSeq 
(version 0.10.0) [242]. The raw counts were normalized using the Relative Log Expression 
(RLE) method and then filtered to exclude genes with fewer than 10 counts across the 
samples [243].  
 
RNA sequencing: Gene Set Enrichment Analysis 
Gene set enrichment analysis (GSEA) was used to further characterize the biology of the 
genes comprising the WGP vs PBS conditions and their differences [244]. Gene sets were 
obtained from the Molecular Signatures Database (MSigDB) for Gene Ontology (GO) 
biological processes and reactome pathways. For each gene set, all tested gene locations in 
the comparison of WGP vs PBS treated control mice were sorted from highest to lowest 
significance using p values. This approach allows highly significant up- and down-
regulated genes to be included within each gene set, an approach that more accurately 
reflects the conditions in a biological pathway. For this analysis, a table of the enriched 
sets is followed by an enrichment plot displaying the profile of the enrichment score (ES) 
score and position of gene set members on the rank ordered list.   
 





Live CD45+ cells were sorted from mouse pancreata, washed and resuspended in 1x PBS 
(calcium and magnesium free) containing 0.04% BSA. Single cells were captured and 
barcoded cDNA libraries were constructed using the Chromium Next GEM Single Cell 3ʹ 
Reagent Kit (v3.1, 10X Genomics) and the Chromium Controller, according to 
manufacturer’s instructions. Libraries were pooled and sequenced using a 28bp x 8bp x 
125bp configuration for read1 x i7 index x read2 on the Illumina NextSeq 500 with the 
NextSeq 500/550 150 cycle High Output Kit v2.5 (20024907). 
 
Since cell sequencing: Gene expression profiling 
Bcl files were demultiplexed into fastq files using the CellRanger software (10X Genomics, 
v3.1.0). The total number of sequenced reads was 506,913,062. The reads were of good 
quality as determined by FastQC [245]. Gene counts were measured using CellRanger 
‘count’, utilizing the cellranger-mm10-3.0.0 reference genome for mouse. A counts matrix 
was generated for each individual sample and one aggregated sample with the expected 
number of cells set at 5,000.  
 
The raw count data determined by CellRanger was used as input to a custom analysis 
pipeline in R which uses a variety of single-cell analysis tools based on Seurat. The knee 
plot (Fig S7B)  displays a graph showing the ranked UMI counts for each cell barcode for 
data aggregated across the three groups. Cells above the inflection point represent possible 
doublets while those below the knee represent background cells. Cell quality control 




characteristics were removed from the analysis: low counts (possible background cells) 
with an FDR cutoff of 0.01 from the DropletUtils [247] function ‘emptyDrops’, high counts 
(possible doublet cells) with more counts than the knee plot inflection point, mitochondrial 
content greater than 30% and ribosomal content greater than 40%. Gene (features) were 
further filtered to remove retired gene identifiers, and genes that were not expressed in at 













Figure M1: scRNA-seq cell counts and Knee plot  
(A) Initial and filtered number of cell barcodes and genes. (B)  Ranking of call cells by 
UMI count of PBS, WGP-3day and WGP-7day, aggregated. Each curve has an associated 







The expression data was normalized using SCTransform [248] where cell cycle genes, 
ribosomal content, and mitochondrial content were regressed. The cells were then clustered 
and dimension reduction was performed using UMAP [249]. Initial cluster names were 
assigned using a modified GSVA [250, 251] enrichment score technique. For each of these 
clusters, the top marker genes were identified. Differentially expressed genes comparing 
each cluster to every other cluster (all pairwise comparisons) was determined using Seurat 
[246] and MAST [252].  
 
Identification of clusters generated with scRNA-Seq 
Non myeloid-derived clusters were classified generally as B-cells (MS4A1), plasma cells 
(SDC1),  CD8+ T-cells (CD3e, C8a), CD4+ T-cells (CD3e, CD4),T-regulatory cells (T-
regs) (CD3e, CD4, FoxP3),  T-cells (CD3e, TRGC1, TRGC2,IL7Ra) and, type 2 innate 
immune cells (ILC2s) (Alox5, KLRG1, Ly6a, Pparg,GATA3, IL-5, IL-13, and Rxrg) [253-
255]. Neutrophils were identified through MMP9, Csf3r, S100A8, S100A8 and ADAM8  
expression, though may be underrepresented in these analyses due to their low RNA 
content and high levels of intrinsic  RNases [256].  Conventional dendritic cells (cDCs) 
were identified through ITGAX  and ITGAE expression and plasmacytoid DCs (pDCs) were 
identified by ITGAX and Siglech. 
 
Phagocytosis assays  
The pancreas of PBS/microparticle injected mice and in-vivo WGP-trained mice were 
harvested 7 days after injection and processed as described previously into a single cell 




in 100 L of this solution for 1 hour at 37C in order to activate the cells. The Invitrogen 
pHrodoTM Green S. aureus BioParticlesTM Phagocytosis Kit for Flow cytometry (Thermo 
Fisher Scientific) was used according to the manufacturer’s instructions. 100 L of the 
reconstituted particles  or  1x106 GFP+ KPC tumor cells were added to the activated 
pancreatic cells and incubated for 1 hour at 37C. Samples were gently vortexed every 15 
minutes. The reaction was stopped by added 1mL of cold PBS. Samples were incubated 
with Fc Block for 10 minutes at 4C, stained for viability, CD45, CD11b and F4/80 for 30 
minutes at 4C, and then analyzed using a BD FACSCanto. For analysis, after gating on 
live cells and CD45, cells that fluoresced in the FITC channel were determined to be 
phagocytic.   
 
Cytotoxicity assay 
The pancreas from WGP and PBS treated mice were harvested and the CD11b+ 
populations were isolated using magnetic CD11b+ MicroBeads (Miltenyi Biotec) and an 
autoMACS Pro Separator (Miltenyi Biotec). Purified CD11b+ cells were then washed and 
counted, and these were plated at a ratio of 1:20 tumor:effector cells in a 96 well plate. All 
experimental samples were run in triplicate. After plating the CD11b+ cells, the ROS 
inhibitor N-acetly-l-cysteine (NAC)  (Sigma Aldrich) was added to one set of PBS and 
WGP derived cells at 1 mM for 1 hour before the addition of 5000 luciferase expressing 
KPC+ pancreatic tumor cells to all wells. After 24 hours, of co-culture, the plates were 
centrifuged and 20 µL of the supernatant was mixed with 100 µL of the Luciferase Assay 
Reagent (Promega). Luciferase activity measured in the supernatant correlated with tumor 




(Femtomaster FB 12, Zylux Corporation). The spontaneous luciferase signal from plated 
tumor cells was subtracted from the measurement of the supernatant.  Luciferase values 
are represented as Relative Light Units (RLUs).   
 
In vivo tumor models of pancreatic cancer   
A KPC cell line on a C57BL/6 background derived from the  LSL-KrasG12D/+; LSL-
Trp53R172H/+; Pdx1-Cre (KPC) mouse model was purchased from Ximbio. These and 
Pan02 cells which were a generous gift from Dr. Yong Lu at Wake Forest University, were 
used in an orthotopic model of pancreatic cancer. A KPC line transfected with GFP and 
luciferase (KPCGFP+Luc+) were also a generous contribution from Dr. Michael Dwinell at 
the Medical College of Wisconsin. These cells were used exclusively in albino C57BL/6 
mice. For tumor implantation, mice were anesthetized using isoflurane, and the abdomen 
of the mice were pepped with betadine and draped in a sterile fashion.  A 2 cm midline 
laparotomy was performed using aseptic technique with sterile instruments. Following 
laparotomy, the pancreas and spleen were externalized. Tumor cells were suspended in ice 
cold PBS and mixed in a 1:1 ratio with basement membrane matrix Matrigel (Corning). 
0.1x106 tumor cells in 50uL of the PBS-matrigel solution were injected into the tail of the 
pancreas using a 30-guage insulin syringe.  The formation of a small bubble indicated 
successful implantation. The peritoneum was closed using coated polyglycolic acid braided 
absorbable 5/0 suture and the skin was closed using silk braided nonabsorbable 5/0 suture. 
(CP Medical).  Buprenorphine was administered for pain management up to 72 hours 





In vivo imaging  
Mice implanted orthotopically with GFP+ Luciferase+ KPC tumor cells were injected IP 
with 150mg/kg of body weight at 100 µL of XenoLight D-Luciferin-K+ Salt 
Bioluminescent Substrate (Perkin Elmer). After 10 minutes, mice were anesthetized with 
isoflurane and placed inside of a Biospace Lab Photon Imager, which is a dedicated low 
light level in vivo optical modality for bioluminescent and fluorescent imaging. Images of 
mice were taken and used to measure tumor size and growth.  
 
Generation of BM chimeras 
To generate BM chimera, B6/SJL (CD45.1) mice were treated with IP PBS or WGP and 7 
days later the BM was harvested. WT mice (CD45.2) were lethally irradiated (950 cGy) 
and  2x106 CD45+ BM cells from the B6/SJL PBS or WGP treated mice were transplanted 
IV. Six weeks later, the peripheral blood of recipients was analyzed to check the success 
of the BM transplant, and mice were implanted with .1x105 KPC cells orthotopically. 14 
days later mice were euthanized and tumor size was assessed.  
 
Combination therapy with anti PD-L1 mAb 
C57BL/6 mice were treated with WGP at day -7 and implanted with KPC orthotopic 
pancreatic tumors on day 0. Mice were treated with 200 µg of anti-mouse anti-PD-L1 
mAb(Bio X Cell) or Rat IgG2b isotype control (Bio X Cell) at day 3, 7 and 11. Mice were 
then monitored for survival.  
 




C57BL/6 mice were implanted with KPC orthotopic pancreatic tumors at day 0 and on day 
4 and 11 mice were given 1mg of IP WGP or PBS. Mice were then monitored for survival.  
 
Statistical analysis  
Results are represented as mean ± SEM. Data were analyzed using a two-tailed Student’s 
t test or Mann-Whitney U-test. Multiple-group comparisons were performed using a one-
way or two-way ANOVA followed by Tukey’s multiple comparisons test. Correlation 
analyses were performed using Pearson correlation coefficient (normal distribution). 
Statistical significance was set at p<.05. All statistical analyses were performed using 
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REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Viability Dye  Invitrogen  Ref #: 65-0865-14 
Anti-mouse CD45, 30-F11 BioLegend Cat # 103129 
RRID: Ab_893343 
Anti-mouse CD11b, M1/70 BioLegend Cat # 101215 
RRID:AB_312798 
Anti-mouse F4/80, BM8 BioLegend Cat # 123115 
RRID: AB_893493 
Anti-mouse CD3, 17A2 BioLegend Cat # 100203 
RRID:AB_312660 
Anti-mouse CD4, GK1.5 BioLegend Cat # 100411 
RRID:AB_312696 
Anti-mouse CD8, 53-6.7 BioLegend Cat # 100721 
RRID:AB_312760 
Anti-mouse CD19, 6D5 BioLegend Cat # 115507 
RRID:AB_313642 
Anti-mouse NK1.1, PK136 BioLegend Cat # 108709 
RRID:AB_313396 
Anti-mouse Ly6C, HK1.4 BioLegend Cat # 128005 
RRID:AB_1186134 
Anti-mouse Ly6G, 1A8 BioLegend Cat # 127607 
RRID:AB_1186104 
Anti-mouse CCR2, 475301 R&D Systems Cat # FAB5538P 
RRID:AB_1071841
4 
Anti-mouse TNF, MP6-XT22 BioLegend Cat # 506305 
RRID:AB_315426 
Anti-mouse IFN, XMG1.2 BioLegend Cat # 505807 
RRID:AB_315401 
Anti-Rat IgG1,  isotype, RTK2071 BioLegend Cat # 400407 
RRID:AB_326513 
Anti-Rat IgG2b,  isotype, RTK4530 BioLegend Cat # 400607 
RRID:AB_326551 
Anti-mouse CD8, 53-6.7 BioLegend Cat # 100755 
RRID:AB_2562796 





Anti-mouse CD4, RM4-5 BioLegend Cat # 100561 
RRID:AB_2562762 
Anti-mouse CD11b, M1/70 BioLegend Cat # 101249 
RRID:AB_2562797) 
Anti-mouse Ly6C, HK1.4 BioLegend Cat # 128039 
RRID:AB_2563783 
Anti-mouse CD19, 6D5 BioLegend Cat # 115547 
RRID:AB_2562806 
Anti-mouse IFN, XMG1.2 BioLegend Cat # 505843 
RRID:AB_2562847 
Anti-mouse IL-12/IL-35 p53, 27537 R+D Systems Cat # MAB 1570 
RRID:AB_2295829 
Anti-mouse IL-17, TC11-18H10.1 BioLegend Cat # 506935 
RRID:AB_2562850 
Anti-mouse CCR2, 475301R R+D Systems Cat # MAB55381R 
Anti-mouse Granzyme B, 12F9B65 BioLegend Cat # 662801 
RRID:AB_2564373 
Anti-mouse TCR, GL3 BioLegend Cat # 118101 
RRID:AB_313826 
Anti-mouse Tbet, 4B10 BioLegend Cat # 644825 
RRID:AB_2563788 
Anti-mouse CD107a, 1D4B BioLegend Cat # 328635 
RRID:AB_2563708 
Anti-mouse TNF (141Pr), MP6-XT22 Fluidigm  Product # 3141012B  
Anti-mouse CD11c (142 Nd), N418 Fluidigm Product # 3142003B 
Anti-mouse IL-2 (144Nd), JES6-5H4 Fluidigm Product # 3144002B 
Anti-mouse CD69 (145 Nd), H.2F3 Fluidigm Product #3145005B 
Anti-mouse F4/80 (146 Nd), BM8 Fluidigm Product #3146008B 
Anti-mouse CD44 (150Nd), IM7 Fluidigm Product #3150018B 
Anti-mouse Ly-6G (151 Eu), IA8 Fluidigm Product #3151010B 
Anti-mouse CD274 (PD-L1) (153 Eu), 
10F.9G2 
Fluidigm  Product #3153016B 
Anti-mouse FoxP3 (158 Gd), FJK-16S Fluidigm Product #3165024A 
Anti-mouse CD279 (PD-1) (159 Gd), 
29F.1A12 
Fluidigm Product #3159024B 
Anti-mouse CD62L (L-Selectin) (160 Gd), 
MEL-14 
Fluidigm Product #3160008B 
Anti-mouse iNOS (161Dy), CXNFT Fluidigm Product #3161011B 
Anti-mouse CX3CR1 (164DY), SA011F11 Fluidigm Product #3164023B 
Anti-mouse IL-6 (167Er), MP5-20F3 Fluidigm Product #3167003B 
Anti-mouse CD206 (169Tm), C089C3 Fluidigm  Product #3169021B 
Anti-mouse C161 (NK1.1)(170Er), PK136 Fluidigm Product #3170002B 
Anti-mouse CD80 (171Yb),  16-10A1 Fluidigm Product #3171008B 
Anti-mouse CD86 (172Yb), GL1 Fluidigm Product #3172016B 
Anti-mouse CD223 (LAG-3) (174Yb), 
C9B7W 




Anti-mouse I-A/I-E  (209Bi), M5/114.15 Fluidigm Product #3209006B 
Anti-mouse CD45 (89Y), 30-F11 Fluidigm Product #3089005B 
InVivoMAb anti-mouse Anti Ly6G, 1A8 Bio X Cell BE0075-1 
RRID:AB_1107721 




Bio X Cell  BE0101 
RRID:AB_1094907
3 
Rat IgG2b Isotype Control (LTF-2) Bio X cell BE0090 
RRID:AB_1107780 
Anti Mouse anti NK1.1 mAb PK136 Made in the 





Anti Mouse anti CD4 mAb GK1.5 Made in the 





Anti Mouse anti CD8 mAb 53-6.72 Made in the 





Chemicals, Peptides, and Recombinant Proteins 
Tris(2-carboxyethyl)phosphine 





HRP-protector peroxidase stabilizer Boca 
Scientific  
222050 
Antibody Stabilizer PBS Boca 
Scientific  
131050 














Brefeldin A  Biolegend  420601 
Collagenase I Sigma C9891 







Hyaluronidase  Sigma  H2126 
Matrigel® Basement Membrane Matrix, 
LDEV-free, 5 mL 
Corning  356234 







Fixation Buffer BioLegend  420801 
Permeabilization buffer BioLegend  421002 
Fluoresbrite® YG Microspheres, 
Calibration Grade 3.00μm 
Polysciences  18861-1 
3.00μm polystyrene Miroparticle  Sigma-
Aldrich  
79166 
MACS Running Buffer Miltenyi 
Biotec 
130-091-221 
HEPES Corning  25-060-CI 
TRIzol Invitrogen 15596018 
Poly-L-Lysine  Advanced 
BioMatrix 
5048 
XenoLight D-Luciferin – K+ Salt 
Bioluminescent Substrate  
Perkin Elmer 12799 






Lipopolysaccharides from E.coli0111:B4 Sigma  L4391-1MG 
.25% Trypsin 2.21 mM EDTA, 1x [-] 
sodium bicarbonate  
Corning  25-053-Cl 
FBS Atlanta 
Biologicals  
Cat #: S11150 




Cat # BAC62-1000 
Lot #171130-0262 




p-SCN-Bn-Deferoxamine Macrocyclics B-705 
sodium carbonate VWR BJ34277-1L 
Oxalic acid, anhydrous Sigma 756888-50G 








Dulbecco’s Phosphate Buffered Saline Sigma  D8537 




2-propanol  Fisher 
Scientific  
A41701 




iScriptTM cDNA Synthesis Kit  BioRad 1708891 
iQTM SYBR® Green Supermix  BioRad 1708880 
RPMI-1640 medium Sigma R8758-1L 
DMEM- high glucose  Sigma  D5796-500ML 
Critical Commercial Assays 
MaxPar MCP9 Antibody Labeling Kit, 
106Cd 
Fluidigm Cat # 201106A 
MaxPar MCP9 Antibody Labeling Kit, 
111Cd 
Fluidigm Cat # 201111A 
MaxPar MCP9 Antibody Labeling Kit, 
112Cd 
Fluidigm Cat # 201112A 
MaxPar MCP9 Antibody Labeling Kit, 
113Cd 
Fluidigm Cat # 201113A 
MaxPar MCP9 Antibody Labeling Kit, 
114Cd 
Fluidigm Cat # 201114A 
MaxPar MCP9 Antibody Labeling Kit, 
116Cd 
Fluidigm Cat # 201116A 
MaxPar X8 Antibody Labeling Kit, 146Nd Fluidigm Cat # 201146A 
MaxPar X8 Antibody Labeling Kit, 149 Sm Fluidigm Cat # 201149A 
MaxPar X8 Antibody Labeling Kit, 154 Sm Fluidigm Cat # 201154A 
MaxPar X8 Antibody Labeling Kit, 156 Gd Fluidigm Cat # 201156A 
MaxPar X8 Antibody Labeling Kit, 162 Dy Fluidigm Cat # 201162A 
MaxPar X8 Antibody Labeling Kit, 165 Ho Fluidigm Cat # 201165A 
MaxPar X8 Antibody Labeling Kit, 166 Er Fluidigm Cat # 201166A 
MaxPar X8 Antibody Labeling Kit, 168Er Fluidigm Cat # 201168A 
MaxPar X8 Antibody Labeling Kit, 173Yb Fluidigm Cat # 201173A 
ELISA MAXTM standard set Mouse TNF- BioLegend  430901 
ELISA MAXTM standard set Mouse IL-6 BioLegend  431301 
Mouse MIF DuoSet ELISA R&D Systems  DY1978 
Invitrogen pHrodoTM Green S. aureus 
BioParticlesTM Phagocytosis Kit for Flow 






Amylase Activity Assay Kit Millipore 
Sigma  
MAK009 
QIAGEN RNAeasy Kit  QIAGEN 74104 
Promega Luciferase Assay Systems 
Luciferase Assay w/ Reporter Lysis buffer 
Promega  E4030 
Chromium Next GEM Single Cell 3ʹ GEM, 








NextSeq 500 High Output Kit v2.5 (150 
cycles)   
Illumina  20024907  
Experimental Models: Cell Lines 
KPC Cell Line  Ximbio  153474 
Pan02 Cell Line  Gift from Dr. 




KPC/FC1242 Luc/GFP clone 3 Gift from Dr. 
Michael 
Dwinell, PhD 




Experimental Models: Organisms/Strains 
Mouse: C57BL/6J The Jackson 
Laboratory  
000664 
Mouse: B6.129S4-Ccr2 tm1Ifc/J (CCR2 -/-) The Jackson 
Laboratory 
004999 
Mouse: Dectin-1 -/-  (Saijo et al, 2007) 
Mouse: NOD.Cg-







































Primers for CCL2: 
Forward: GGTCCCTGTCATGCTTCTGG  
Reverse: GCTGCTGGTGATCCTCTTGT 
  
Software and Algorithms 
CyTOF Workflow  Nowicka M., 

























































































Amicon Ultra-.5 centrifugal Filter Unit, 
.5mL V-bottom, 8-pack 3kDa 
Millipore 
Sigma  
UFC500308 (3 kDa) 
 
Amicon Ulrta-.5 centrifugal Filter Unit, 




Amicon Ultra-.5 centrifugal Filter Unit, 




Eppendorf protein LoBind Tubes, 1.5 mL Eppendorf  0224431081 
polyglycolic acid braided absorbable 5/0 
suture 
CP Medical  421A 
silk braided nonabsorbable 5/0 suture CP Medical  682S 
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